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Cystic fibrosis (CF) is the most common, fatal genetic disease in the Caucasian population caused 
by loss of function mutations in gene encoding for the cystic fibrosis transmembrane conductance 
regulator (CFTR). CFTR is expressed at the apical surface of epithelial cells of different organs, such 
as: lungs pancreas, gut, and testes. For this reason even if in CF the pulmonary manifestations are 
the most severe, CF is considered a multi-system disease, which affects several bodily districts.  
The new challenge for the CF therapy is based on the development of small molecules able to 
rescue the function of the mutated CFTR. Many pharmacological agents have been designed to 
increase the surface level of mutated CFTR (correctors), as well as its plasma membrane (PM) 
activity (potentiators). 
Recently, combined therapy that includes a corrector of the CFTR folding (lumacaftor or VX-809) 
and a potentiator of the channel activity (ivacaftor or VX-770) called Orkambi®, was approved for 
CF patients homozygous for the deletion of phenylalanine at position 508 (F508del), the most 
common CF-causing mutation. Unfortunately, clinical studies revealed that the effects of 
Orkambi® on lung function were modest, due to low stability of rescued F508del-CFTR at the PM 
level. 
Indeed, many factors contribute to PM CFTR stability, including its compartmentalization in PM 
macromolecular complexes composed of phospholipids, sphingolipids, with particular regards for 
monosialoganglioside 1 (GM1), and scaffolding proteins such as ezrin and NHERF-1. 
Interestingly, it has been proved that in bronchial epithelial cells the lack of CFTR in the cell PM, 
such as in the case of the patients carrying the mutation F508del, is associated with a decreased 
content of GM1. By performing photolabelling experiments, I demonstrated for the first time that 
GM1 and CFTR at PM level reside in the same microdomain, suggesting a direct interaction 
between them. Then I investigated on the potential effect of the exogenous administration of 
ganglioside GM1 on the PM stabilization and function of F508del-CFTR rescued by Orkambi® 
treatment. In particular, I proved that in CF bronchial epithelial cells GM1 antagonizes the negative 
effect of VX-770, increasing F508del-CFTR maturation and its channel activity by the recruitment 
of the scaffolding proteins NHERF-1 and ezrin. 
Taken together the results obtained during my PhD project pointed out the role of GM1 as 
possible adjuvant to Orkambi® therapy to restore the function of F508del-CFTR.
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Cystic Fibrosis 
Cystic fibrosis (CF) is the most common life-limiting autosomal recessive disease among 
Caucasians, affecting approximately 1 every 2500-4000 newborns; this pathology is caused by 
mutations of a gene which encodes for a chloride-conducting transmembrane channel called 
Cystic Fibrosis Transmembrane Conductance regulator (CFTR). CFTR regulates anion transport and 
mucociliary clearance in the airways, and its functional damage results in mucus retention and 
chronic infection which causes local airway inflammation. CFTR is expressed at the apical surface 
of epithelial cells of different organs, such as: lungs, pancreas, gut, and testes. For this reason, 
even if in CF the pulmonary manifestations are the most severe, it is considered a multi-system 
disease which affects several bodily districts [1]. 
During the past six decades, the average age of survival has increased progressively, and thanks to 
the current CF therapies is now 40 years in developed countries [2]. 
 
CFTR genetics: gene and tissue expression 
The gene responsible for the CF disorder called CFTR, was identified in 1989 and belongs to the 
long arm of chromosome 7 (7q31). The gene spans 190 Kb of genomic DNA and is composed of 27 
exons, which encode for a 1480 aa protein. 
The number of identified sequence variants in the CFTR gene has now exceeded 2000, although 
fewer than 200 have been definitively proved to be disease-causing. 
The full-length CFTR mRNA contains 6128 nucleotides and all the CFTR transcription mechanisms 
start from the same site but there are also some mechanisms of alternative splicing. The promoter 
region is characterized by consensus binding sites for different transcriptions factors as AP-1, SP1, 
GRE, CRE, C/EBP. In addition, CFTR expression is regulated by hormone in both males and females 
[3]. 
The expression of CFTR was deeply analysed in both rodents and humans [4]. CFTR mRNA is 
constitutively expressed in sweat gland and in gastrointestinal tract starting from early 
development, [5] and it is maintained for the all-adult life. 
Besides, the lung expression, CFTR was shown to be expressed at high levels in the pancreatic duct 
epithelium, and at lower levels detected in the larger intra- and interlobular ducts. High levels of 
CFTR expression were also seen in the crypts of the small intestinal epithelium.  
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CFTR is also expressed in mucin secretory cells, in gallbladder epithelia and in the Brunner glands. 
Measurable levels of CFTR were also detected in female and male reproductive tissue and organs, 
such as cervix, endometrium, fallopian tubes, and ovary as well as in epididymis head. Low and 
intermediate levels of CFTR transcripts can also be found in kidney, thyroid and salivary gland [6]. 
The expression patterns of CFTR in the fetus are maintained postnatally, with the exception of the 
respiratory system. Although high levels of CFTR expression are found in the epithelium of the 
airways in the fetal lung, this is in marked contrast to the relative lack of expression detected in 
the adult lung [7]. On the other hand, the expression in submucosal gland is detected only after 
birth, and it is not measurable in fetus, indeed in adult respiratory tissue the main site of 
expression of CFTR is the serous submucosal gland [3, 7, 8]. 
The mechanisms controlling the complex expression pattern of CFTR are not yet totally 
understood. The CFTR promoter has a housekeeping-type promoter, it is rich in CpG, without TATA 
box, and contains a number of putative Sp1 (specificity protein 1) binding sites [9, 10].  
While the promoter is important for CFTR basal expression, it doesn’t explain the complex tissue 
specific regulation of its expression, indeed, there are distal cis or trans-acting regulatory elements 
which are critical regulators of this process. 
In sexually immature females and ovariectomized mature females the estrogen treatment 
upregulates CFTR levels in the uterine epithelium and the oviductal mucosa by the binding with 
glucocorticoid response elements located in the CFTR promoter [7]. 
 
CFTR structure 
CFTR is a membrane protein, belonging to an ABC subfamily [11], with the typical ABC transporter 
structure composed of two transmembrane domains (TMDs), four intracellular linkers, (ICL1-ICL4), 
and two nucleotide binding domains (NBDs) [12]. CFTR has also an additional regulatory (R) region, 
as well as long N- and C-terminal extensions of about 80 and 30 residues in length, respectively 
[13].  
TMDs are composed of six membrane-spanning α-helices and they are predicted to form a pore 
for ions passage. NBD1 has an additional insertion of 35 residues and NBD2 has 80 residues 
extension at its end, if compared with other ABC proteins. These additional peptides may regulate 
CFTR channel interaction with other cellular molecules.  
The regulatory region R is a random coil highly charged, of 200 residues in length and is 
characterized by several consensus sequences (12 serines and 8 threonines) for protein kinase A 
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(PKA) phosphorylation. The four intra-cellular loops are predicted to interact and transduce 
information between TMDs and NBDs [14]. CFTR forms a channel at epithelial apical cell 
membranes [15-17], regulating Cl−/HCO3
−exchange [19, 20]. 
CFTR in PM is present in 3 possible status: open, closed and open-ready. The open-ready 
conformation doesn’t allow chloride flux but it is poised to a rapid transition into the open state 
upon specific stimuli. CFTR channel activity is also PKA dependent on the phosphorylation of the 
region R and on intracellular availability of ATP. Structurally, the model connects ATP binding with 
the formation of a NBD head-to-tail sandwich heterodimer and probably this is responsible for the 
induction of conformational changes in the TMDs via NBD-TMD coupling helices that open the 
channel gate. The channel gate closes after ATP hydrolysis and comes back to inward-facing 
conformation [21]. 
More recently, evidence has proved that R region steric block can be alleviated via other 
mechanisms: calcium-loaded calmodulin was found to bind to the non-phosphorylated R region α-
helices leading to channel activation [22]. 
Calmodulin binding inhibits phosphorylation by Protein Kinase A (PKA) and PKA phosphorylation 
inhibits calmodulin binding. This results in a complex interconnection in which PKA 
phosphorylation can synergize with the activating effects of calcium on CFTR or decouple CFTR 
from calcium activation [23]. Recently, it has been demonstrated that other binding partners of 
the R region include the C terminus of CFTR, which contains a PDZ-binding motif, the SLC26A3 
transporter, which can co-regulate CFTR [24, 25]. 
 
 
Figure 1: Theoretical domain organization of CFTR at the apical membrane based on analysis of crystal 
structures and structural homology models [26] 
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CFTR biosynthesis 
CFTR biosynthesis begins in the endoplasmic reticulum (ER) with the folding of the cytosolic 
domains, towards the acquisition of a fully folded native structure. CFTR folding starts early during 
its translation, which takes place in multiple cellular compartments along the secretory pathway 
(Figure 2). This process is assessed by the ER quality control system that allows the exit of folded 
proteins and targets unfolded/misfolded CFTR to the degradation. 
The first step of folding control occurs in the ER, by chaperons protein such as Calnexin, Aha, and 
HSP40/70/90. Both inter and intra-domain folding are required for ER exit. If allowed to leave the 
ER, CFTR is modified at the Golgi and joins the post-Golgi compartments to be delivered to the PM 
[27].  
After proper folding, CFTR moves from the ER to the Golgi apparatus, where the glycan moieties 
are processed, and finally, mature CFTR is carried in vesicles from the trans-Golgi network (TGN) to 
the PM. At the PM, CFTR levels result from a balance between membrane delivery (anterograde 
trafficking), endocytosis, and recycling. The PM provides the final stages of CFTR maturation, 
indeed, at the PM level CFTR takes part in an interactome, which includes members of Rab and 
Rho families, GTPase and cytoskeleton proteins, such as the PDZ-interacting NHERF protein [21]. 
Two glycosylations at 4th extracellular loop, on the residue 894 and 900, characterize the correct 
and mature form of CFTR, even if this modification is not essential for the channel activity and for 
its PM localization. In fact, there are other different post-translational modifications such as 
methylation, palmitoylation, and phosphorylation which are important for the correct folding, the 
biological activity and finally, the stability of the protein [21]. 
 
Introduction 
11 
 
 
Figure 2: Successive steps of CFTR synthesis, trafficking and degradation. Figure adapted from [27] 
 
CFTR interactors and microenvironment 
Once at the cell surface, CFTR stability is regulated by multiple protein interactors which regulate 
not only anterograde traffic to the PM, but also its endocytosis and recycling to reach a tight 
modulation of CFTR membrane levels [28-30]. 
Interactions at both the N-terminus and C-terminus of CFTR have been reported to regulate 
channel activity, including PDZ proteins such as NHERF-1 and CAL or other membrane proteins 
that interact with CFTR through large macromolecular complexes.  
Recent works have demonstrated that the second messenger cAMP has a role in regulating CFTR 
PM stability. Intracellular cAMP effects are mediated by cAMP-dependent PKA, which directly 
phosphorylates CFTR's R domain, but interestingly, a family of guanine nucleotide-exchange 
factors, called EPACs, have been also discovered to respond to cAMP levels but they do not lead to 
PKA activation [31, 32]; moreover, EPACs regulate cell-to-cell and cell-to-matrix adhesion, 
cytoskeletal rearrangements, and cell polarization. 
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In addition, the interaction with membrane lipids also seems to have a crucial role in CFTR stability 
and function, in particular, recent works have described interactions with cholesterol, that 
regulate the distribution and dynamics of CFTR in PM [33, 34]. Moreover, they have suggested a 
role of sphingomyelin for the regulation of CFTR activity, by sphingomyelin-mediated signalling 
pathways. 
Interestingly, it has been proved that in bronchial epithelial cells the lack of CFTR in the cell PM, 
such as in the case of the patients carrying the mutation F508del (the mutation with highest 
frequency), is associated with a decreased content of GM1 [35], suggesting a relationship between 
the channel and this ganglioside. 
 
 
Figure 3: CFTR regulation and interactions. Image modified from Farinha et al 2017 [36] 
 
Cystic Fibrosis Epidemiology 
Nowadays, the worldwide distribution of CFTR mutations that leads to CF, is still incomplete, for 
example in Eastern Asia the disease named panbronchiolitis is often associated with CFTR 
mutations, but its phenotype is completely different with respect to CF, in fact there isn’t the 
involvement of pancreas and sweat glands. Although, CF is most prevalent in Caucasians (1 in 
2,500), it is a panethnic disease in North America, found in all ethnicity, including African-American 
(1 in 15,000), Hispanic-American (1 in 13,500), and Asian-American (1 in 35,000).  
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The great phenotypic variability of CF has been shown to implicate not only the type of CFTR 
mutations, but also other genetic factors such as modifier genes, and environmental factors 
including the lifestyle [37, 38]. 
Most of CF patients suffer from classic CF, characterized by a multisystemic organs impairment 
and a sweat chloride concentration of >60 mmol/L. 
They may have exocrine pancreatic insufficiency or pancreatic sufficiency. CF can have a severe 
course with fast progression of symptoms or a milder course with less lung deterioration. Classic 
CF patient mortality is mainly due to progressive respiratory disease [39]. 
Non-classic CF includes individuals with at least one CF phenotypic characteristic and a normal 
(<30 mmol/L)or borderline (30–60 mmol/L) sweat chloride level. These patients have both multi- 
and/or single-organ involvement. Most of them have exocrine pancreatic sufficiency and milder 
lung disease. 
 
CFTR mutations 
Over 2000 mutations have been identified in the CFTR gene [7], including missense, frameshift, 
splicing and nonsense mutations, inframe deletion, and insertions. On the basis of the effect on 
CFTR function, the mutations are classified into six major classes: class I, II and III mutations are 
associated with no residual CFTR function and the patient with these kind of mutations show a 
severe phenotype. While patients with mutations belonging to class IV, V and VI, show some 
residual CFTR function, and have a mild lung disease and pancreatic sufficiency [40]. 
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Figure 4: Classification of CFTR mutations [41] 
 
Class I: mutations preventing the production of a full-length CFTR protein 
Class I mutations result in the total or partial lack of production of a functional CFTR protein. Such 
mutations may be due to a nucleotide substitution which introduces an in-frame premature 
termination codon (W1282X, G542X and R1162X), a frame-shifting insertions or deletions, 
mutations at the invariant dinucleotide splice junctions of a PTC, resulting in complete skipping of 
an out of frame exon, and a complete or partial deletion of the CFTR gene or a rearrangement in 
the gene which can alter the exon sequence [42]. G542X is the most frequent mutation of this 
class and leads to a reduced steady state level of mRNA, caused by the presence of a premature 
stop codon in its sequences. 
 
Class II: mutations altering the cellular processing of the protein 
Class II mutations are associated with a defective processing due to misfolding of the protein and 
may be found within any domain of the CFTR. Even if it is translated into full-length polypeptide, 
the misfolded protein is retained into the ER, targeted to degradation by the 
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ubiquitin/proteasome pathway, rather than trafficked to the PM. The most frequent CF mutation 
of this class is the F508del. It has been shown that F508del leads to energetic and kinetic instability 
of the NBD1 domain due to improper local folding. This mutation causes the most severe 
phenotype in the patients. 
 
Class III: mutations disturbing the regulation of the Cl−channel 
These mutations are frequently located in the ATP binding domains (NBD1 and NBD2) and are 
referred to as gating mutations; this group of mutations is mainly composed of missense 
mutations. The produced CFTR can reach the PM but has decreased channel opening time and 
decreased chloride flux, caused by resistance to activation by protein kinase A. The most described 
mutation of class III is p.Gly551Asp [16]. 
 
Class IV: mutations altering the conduction of the Cl−channel 
These mutations influence mainly the membrane spanning domains implicated in the constitution 
of the channel pore. The missense mutations located in these regions produce a protein which is 
inserted in the membrane, but with a reduced channel conductance. The p.Arg117His mutation is 
the best-characterized class IV mutation. Recently, the subclass IVb has been identified in relation 
to mutations regarding only defect in CFTR bicarbonate conductance. 
 
Class V: mutations reducing the amount of functional CFTR protein 
Most of these class V mutations reduce the total amount of CFTR protein by affecting pre-mRNA 
splicing. These splice site mutations can induce complete or partial exclusion of an exon. As result, 
CFTR is fully functional in the PM but with lower content. The most frequent and well-studied is 
the skipping of exon 10 [39]. 
 
Class VI mutations destabilize the channel in post-ER compartments and/or at the PM 
This class is the most recent and includes those mutations which can destabilize CFTR in the post-
ER compartments or at the PM, by reducing its conformational stability [43] and/or generating 
additional internalization signals [44]. These mutations can accelerate PM turnover and reduce 
apical PM expression [42,43]. Class VI mutation has recently been combined with class V as 
mutations leading to a reduced amount of functional CFTR protein [21], [39], [28]. 
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Clinical feature of Cystic Fibrosis 
The faulty secretion of chloride, sodium and water followed by the formation of viscous mucus at 
the respiratory level, and digestive and reproductive systems, represents the central problem in 
patients with CF, while the insufficiency in the reabsorption of these ions at the level of sweat 
glands is of lower significance. 
Respiratory diseases are present in more than 90% of CF patients. CF usually shows signs of 
manifestations already in the first months after birth featuring pertussis-like cough, several 
bronchiolitis or obstructive bronchitis. These symptoms are due to difficulties with elimination of 
hyperviscous secretions and pulmonary hypoventilation [45]. 
 
Cystic fibrosis lung disease and inflammation 
Lung disease is the major cause of mortality in CF patients, despite CF lung disease is primarily an 
infectious disorder, the consequent and associated inflammation is both intense and ineffective in 
eliminating pathogens. Persistent high-intensity inflammation leads to structural damage of the 
airways and impaired lung function that may result in respiratory failure and death. Several 
defective inflammatory responses have been linked to CFTR deficiency including innate and 
acquired immunity dysregulation, cell membrane lipid abnormalities, various transcription factor 
signalling defects, as well as altered kinase and toll-like receptor responses [46]. The most 
common pathologic findings are bronchiectasis, airways obstruction and chronic infection driven 
by different bacteria, in particular by Pseudomonas aeruginosa [47, 48]. The other persistent 
bronchopulmonary infections are driven by Staphylococcus aureus, Burkholderia cepacia and 
several other pathogens, leading to chronic airway and systemic inflammation, tissue destruction, 
and respiratory insufficiency [46]. 
Several studies demonstrate the large number of defects of the CF lung disease and inflammation, 
directly or indirectly correlated to CFTR, such as airway surface liquid and mucociliary clearance, 
the lower pH of airway surface liquid and sphingolipids abnormalities [49-51].  
The airway mucus is a dynamic, complex and viscous colloid which can continuously modify in 
response to different signals. The mucus contains different molecules as antibacterial defensins, 
immunoglobulins, inorganic salts and the proteins mucins. Thanks to these components, the 
airway mucus is able to cover several functions, such as to create a protective barrier against toxic 
products and to clear pathogens. The mucus must be sufficiently fluid to allow the elimination of 
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particles and pathogens. The presence of CFTR influences the characteristics of the airway surface 
liquid and mucus layer [52, 53]. 
The water content of airway surface liquid is regulated by CFTR, by its capacity to secrete chloride 
ions and control sodium adsorption. The impaired regulation of sodium and chloride content in CF, 
leads to a defective osmotic pressure, an increased absorption of water and consequently to a 
dehydration of the airway surface liquid [50, 51, 54, 55]. As a consequence, there is the formation 
of a very viscous mucus unable to eliminate bacteria, leading to a chronic retention of pathogens 
and a strong inflammatory response [46, 56]. 
Another important parameter in CF is pH: the pH of CF airway surface liquid is eight-fold more 
acidic than that of individuals without CF [57]. CFTR is essential for normal bicarbonate secretion 
from cultured bronchial epithelial cells and from native small airways [58-60]. The low pH at the 
airway surface results in the inactivation of antimicrobial peptides thus creating a host defense 
defect [61]. Furthermore, recent evidence suggests that CFTR-dependent bicarbonate is important 
in defining the expansion and solubilization of mucin granules as well as the density of airway 
mucus. Moreover, local pH is essential to the correct function of several proteins, in particular, the 
proteins named mucins and principally MUC5A, MUC5B, and MUC2, which are able to attract 
water in the mucus [62]. These proteins can be transmembrane, on the apical surface of epithelial 
cells, or can float as a gel, but both these kinds of mucins are localized in the periciliary space 
forming a protective barrier. The absence of bicarbonate causes the formation of dense layer of 
mucins, tightly adherent to the epithelium surface. [46, 54, 63]. 
In addition, the low pH at the airway surface, results in the inactivation of proteins with 
antimicrobial properties [64]. 
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Figure 5: Mutation in the CFTR gene prevents Cl− from being secreted and there is unrestrained Na+ 
absorption, leading to defective mucus clearance [65] 
 
Current therapy 
 
Lung disease treatment 
The treatment of lung disease in CF is central: oral antibiotics are used prophylactically in some 
countries to prevent S. aureus infection, despite the concerns of increasing risk of P. aeruginosa 
infection. In children, repeated infections are treated with oral antibiotics aimed at eliminating S. 
aureus and H. influenza colonization. People with CF have recurrent exacerbations of disease. 
Pulmonary exacerbations are episodes in which there is an increase in symptoms of chronic lung 
infection, they are associated with increased breathlessness, reduced exercise tolerance and 
systemic symptoms associated with an acute phase inflammatory response. Episodes of 
pulmonary exacerbation usually continue for several days and are treated with antibiotics and 
increased airway clearance. For S. aureus and H. influenzae infection, oral antibiotics are usually 
administered [66-68]. In patients chronically infected with P. aeruginosa or other Gram negative 
bacteria, these episodes usually need treatment with intravenous antibiotics. In addition to 
antibiotic therapy, patients with CF have to take also anti-inflammatory drugs, both non-steroidal 
anti-inflammatory drugs (NSAIDs) and steroidal anti-inflammatory drugs such as corticosteroids. 
As pulmonary damage in CF may occur as a consequence of inflammation, it has been 
hypothesized that prolonged use of NSAIDs may prevent progressive pulmonary deterioration and 
respiratory morbidity [69]. Furthermore, inhaled corticosteroids are often used to treat children 
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and adults with CF, in fact they have the potential to reduce lung damage arising from 
inflammation, as well as their effect on symptomatic wheezing [70, 71].  
To ameliorate the breathing conditions, physiotherapy plays an important role in the management 
of CF [72]. 
 
Pancreatic and biliary disease 
Epithelial cells in the pancreatic and biliary ducts are also involved in the CFTR dysfunction leading 
to pancreatic insufficiency, which associated to biliary cirrhosis though occurring in less than 10% 
of patients, and it can be treated with pancreatic enzyme replacement therapy [73, 74]. More 
commonly, people with CF have variably abnormal liver function, but just a small group of these 
patients develop cirrhosis or portal hypertension, whose unique treatment is the liver transplant 
[75, 76]. 
 
Innovative therapies 
The new therapeutic strategies are aimed to develop drugs that correct the basic defect in CFTR 
function.  
 
Gene and molecular therapies 
Since the cloning of the CFTR gene, several studies have shown that CFTR function can be restored 
in the nose of CF patients by the transfection of the wild-type (WT) protein. The first major study 
of lung delivery has recently been reported and has shown some effects on important clinical 
parameters of FEV1, but this study suggests also that substantially more efficient vectors and 
delivery systems are required to achieve sufficient expression of CFTR [75]. 
 
CFTR chaperons 
This strategy is based on the development of small molecules targeting CFTR as chaperons which 
are able to facilitate the folding of mutated CFTR and restoring its function.  
The first proposed molecule was N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide (VX-770, ivacaftor); this drug was identified through 
highthroughput screening and subsequently modified to optimize its therapeutic effect [77]. 
Preclinical studies have shown that ivacaftor corrects CFTR-mediated chloride transport in most 
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class III mutations, class IV mutations in human bronchial epithelial cell cultures [78, 79], [80], [81], 
and may be administered to patients starting from 6 year of age [82].  
 
 
Figure 6: Ivacaftor structure 
 
Ivacaftor is on clinical use for the patients carrying mutations G551D, with the commercial name 
of Kalydeco®. 
The second chaperon strategy has been developed to target patients who are homozygous for the 
Phe508del mutation. Indeed, these two chaperons allow to restore trafficking of CFTR and to 
make it functional. F508del CFTR mutation impairs CFTR processing in the ER by preventing the 
properly protein folding [83], [84]. Misfolded F508del-CFTR is retained by the ER and degraded, 
reducing F508del-CFTR delivery to the cell surface. In this frame, the most promising molecule was 
the corrector VX-809. 
 
 
 
Figure 7: Lumacaftor structure 
 
VX-809 acts early in CFTR biosynthesis to modulate the conformation of MSD1 and thereby 
suppresses folding defects in F508-CFTR and related MSD1 mutants. The combined therapy with 
the potentiator VX-770 is on clinical use in children older than 12 years, and has the commercial 
name of Orkambi®. 
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However, clinical studies revealed that the effect of Orkambi® on lung function is modest and it 
was proposed that this modest effect relates to a negative impact of VX-770 on the stability of 
F508del-CFTR in PM. Recent study shows also that there is a potential non-specific effects of VX-
770 on the lipid bilayer and suggests that this may account for its destabilizing effect on VX-809- 
rescued F508del-CFTR [85]. 
 
Sphingolipids  
PM is composed of an extremely complex lipid pattern including glycerophospholipids, cholesterol 
and sphingolipids [86]. Despite the fact that glycerophospholipids and cholesterol are the main 
lipids which compose eukaryotic cell membranes [87], nowadays emerging evidences support the 
important role of Sphingolipids (SLs) [88]. 
SLs are amphipathic molecules, mainly associated with the external leaflet of the cell PM, 
characterized by a hydrophobic group inserted in the lipid bilayer and a hydrophilic head of 
different complexity which protrudes toward the extracellular environment [89]. 
They have a common structure which comprises a backbone called “long-chain” or “sphingoid” 
base, which is formed by a 2-amino-1,3-dihydroxy-octadec-4-ene, an amino alcohol called 
sphingosine. Sphingosine has four different chemical configuration, but only the 2S, 3R is found in 
nature. It is the most abundant “sphingoid” base detected in mammals and is typically present 
linked with a long or very long fatty acid-chain, through an amide-bound. The fatty acid chains are 
predominantly composed of 14 to 36 carbon atoms in length and are usually saturated [90].  
The N-acylated form of sphingosine is called Ceramide (Cer), and is the hydrophobic lipid moiety of 
sphingolipids. Cer is the starting point for the biosynthesis of the more complex sphingolipids and 
glycosphingolipids (GSLs) [89]. 
The hydrophilic head group R of sphingolipids is composed of phosphocoline in the case of 
sphingomyelin or of an oligosaccharide chain in the case of glycosphingolipids. The Gangliosides 
are a particular class of glycosphingolipids which have the oligosaccharide that contains a sialic 
acid residue [89]. 
Sphingolipids are a class of lipids essential for cell membranes architecture, but in the last two 
decades many studies have proved that SLs are not only structural components of biological 
membranes, but they also play other important roles in several cellular processes [91]. 
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Indeed, a large variety of specific SLs have been shown to modulate the cellular signaling pathway 
[92]. 
 
Ceramide                                                                    Sphingosine 
Figure 8: Chemical structure of ceramide and sphingosine 
 
Biosynthesis 
Sphingomyelin and glycosphingolipid biosynthesis in mammals requires the intracellular formation 
of the membrane anchor, the ceramide [93] and the subsequent addition of single component of 
the hydrophilic head [94]. Both events are coupled to intracellular movement of metabolic 
intermediates and final products to the PM [95]. The variety of naturally occurring complex 
sphingolipids can be largely attributed to the combination of enzymes with transferase activities, 
which are expressed in specific cell types, and the brain is the organ where functional aspects of 
glycolipids are most evident. 
 
Ceramide 
The production of Cer in mammalian cells occurs through three different metabolic ways: de novo 
biosynthesis, complex sphingolipids catabolism and sphingosine recycling. 
De novo biosynthesis of Cer, starts with the condensation of the amino acid L-serine with a fatty 
acyl coenzyme A, usually palmitoyl coenzyme A, to 3-ketosphinganine and it is catalysed by the 
enzyme serine palmitoyl transferase [96], [97], [98]. In the following NADPH-dependent reaction, 
3-ketosphinganine is reduced to d-erythro-sphinganine by 3-ketosphinganine reductase [99]. 
Sphinganine is subsequently acylated to dihydroceramide by a N-acyltransferase (ceramide 
synthase) [100], [101]. The major part of the dihydroceramide pool is desaturated to Cer in the 
dihydroceramide desaturase reaction [102]. 
Cer is also generated during the catabolism of all complex sphingolipids. The catabolism occurs in 
the lysosomes by the action of specific glycohydrolase which removes single saccharidic units from 
the not reducing extremity of the oligosaccharides. Sphingomyelin (SM) hydrolysis is catalyzed by 
the action of sphingomyelinases (SMases) [103]. Different forms of SMases are known, and are 
characterized by specific optimum pH, subcellular localization, cation dependence. Ceramide 
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synthase is able to use as substrate both sphingosine and sphinganine with similar efficiency, so 
Cer can be also formed by N-acylation of sphingosine produced by the catabolism of complex 
sphingolipids. 
 
Sphingomyelin 
SM biosynthesis occurs on the luminal part of Golgi membranes [104]. It is formed by the transfer 
of phosphorylcholine from the phospholipid phosphatidylcholine, onto the 1-hydroxyl group of 
Cer, with the liberation of diacylglycerol. 
 
 
Figure 9: Sphingolipid neo-biosynthetic pathway, image from Aureli et al 2016 [105] 
 
Complex GSLs 
Glycosyltransferases catalyze the reaction of transfer of a specific carbohydrate, from the sugar 
nucleotide (UDP-Glucose, UDP-Galactose) to a specific type of acceptor, as ceramide or the non-
reducing end of a carbohydrate chain attached to Cer [106]. 
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The first step of glycosylation leads to the production of glucosylceramide (GlcCer), whose 
formation is catalyzed by a ceramide glucosyltransferase, called GlcCer synthase [107], in the 
cytosolic side of the early Golgi membrane [108]. The neo-synthetized GlcCer can follow two 
different ways: it reaches the PM or it can be translocated to the luminal side of the Golgi, where 
the GlcCer is further glycosylated by different glycosyltransferase to form more complex 
glycosphingolipids. 
The addition of a galactose residue from UDP-Gal to GlcCer, driven by a galactosyltransferase, 
leads to the formation of Lactosylceramide (LacCer).  
One of the major branch of metabolism of LacCer is the formation of ganglio series. The 
gangliosides are a class of GSLs characterized by the presence of sialic acid on their oligosaccharide 
chain. This class is particularly abundant in the cell of the central nervous system. 
The biosynthesis of the complex ganglioside occurs in the lumen of the Golgi apparatus by 
different glycosyltransferase. The GM3 synthase or sialyl-transferase is responsible for the 
sialylation of LacCer to form GM3. The other downstream metabolites in this pathway are formed 
by analogous reactions; GM3 is converted to GM2 by GM2 synthase or β-galactosamynil 
transferase, which transfers an N-acetylgacatosamine to GM3, and GM2 is converted to GM1 by 
GM1b synthase.  
Neo-synthetized glycosphingolipids reach the PM through the exocytotic vesicular traffic. 
In addition, the neo-synthesized Cer, in Golgi apparatus, can be used for Sphingomyelin 
biosynthesis [109].  
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Figure 10: Ganglioside biosynthesis: All enzymatic steps (possibly except formation of LacCer) take place at 
the luminal surfaces of the Golgi membranes. 
 
 
Catabolism  
 
Lysosomal Glycolipid Degradation 
Constitutive glycolipid degradation occurs in the acidic compartments of the cells, the endosomes 
and the lysosomes. Within the digestion of cellular membranes, cellular glycolipids are also 
cleaved into their building blocks. To this purpose, parts of the PM are endocytosed and trafficked 
through the endosomal compartment to the lysosomes. Lysosomal glycosidases sequentially 
cleave off the sugar residues from the non-reducing end of their glycolipid substrates. The 
resulting monosaccharides, sialic acids, fatty acids and sphingoid bases can leave the lysosome and 
are used within salvage processes or are further degraded. 
SLs metabolic homeostasis is obtained with the balancing of biosynthesis, degradation and 
recycling [110]. The central hub of SL anabolism is the vesicular transport of neo-biosynthesized 
SLs from the ER and Golgi apparatus to the PM.  
Moreover, metabolic turnover and degradation of PM sphingolipids are processes occurring in the 
lysosomes, which are the acidic compartments of the cells, by the presence of specific acidic 
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hydrolases [111]. The degradation process consists in the remodeling of the hydrophilic head, 
driven by the lysosomal glycosidase from the non-reducing end of the glycolipid substrates. The 
molecules resulting from the catabolism can leave the lysosomes and can further be degraded or 
used again to form more complex structures [112].  
For example, during the ganglioside catabolism, GM1 is cleaved to GM2 by β-galactosidase. The 
resulting GM2 is then degraded to GM3 and N-acetyl-galactosamine through the action of β-
hexosaminidase A (HexA). The β-hexosaminidases are dimeric enzymes composed of two different 
subunits α and β. The different possible dimerization of their subunits leads to three different 
isoforms of the enzymes: Hex A, Hex B and Hex S [113]. 
GM3 is a substrate of sialidase Neu1 and Neu3, which leads to the formation of LacCer and sialic 
acid. Sialidases are glycohydrolases that catalyze the removal of α-glycosidically linked sialic acid. 
Four different isoforms have been isolated from four different genes: Neu1, Neu2, Neu3 and Neu4 
[114]. Neu1, Neu2, Neu3 are predominantly localized in the lysosomes, cytosol and PM 
respectively. Neu4 is present in mitochondria and ER. 
The degradation of LacCer is driven by β-galactocerebrosidase, which removes galactose obtaining 
GlcCer [115].  
The GlcCer obtained by the reaction of β-galactocerebrosidase is further degraded to ceramide by 
the action of β-Glucocerebrosidase (GCase), a lysosomal-associated enzyme that hydrolyze the 
glycosidic linkage of GlcCer producing ceramide and glucose, and is irreversibly inhibited by 
conduritol B Epoxide (CBE). Besides SM is converted to Cer by sphingomyelinase (SMase).  
In the eukaryotic cells there are acid sphingomyelinase (aSMase) and neutral sphingomyelinase. 
The acid one is principally located in lysosomes [116]. 
 
Plasma membrane sphingolipids metabolism  
Several process are responsible for the PM sphingolipids’ pattern and content. The main are neo-
biosynthesis in ER and Golgi apparatus, the membrane turnover with final lysosomal catabolism 
and vesicles shedding.  
Moreover, some recent data reported that enzymes involved in the sphingolipids metabolism are 
able to modify the sphingolipids head group directly at the PM level [117]. 
Indeed, some of the same enzymes of the sphingolipids biosynthesis and catabolism are found to 
be associated with the cell surface. It has been observed that these enzymes are often available as 
a series of couple that catalyze the same reaction in the opposite direction, contributing to the in 
Introduction 
27 
 
situ modifications of SL composition. These phenomena lead to very important biological 
consequences, considering that they could be instrumental to modulate cell function, with no 
involvement of the complex intracellular metabolic machinery.  
For instance, it has been demonstrated also the presence of β-hexosaminidase A at the PM level, 
in combination with the β-hexosaminyl transferase. 
A particular case is represented by a PM-associate sphingomyelin synthase (SMS2) because it is 
genetically distinct from the Golgi’s one. SMS2 is present in combination with SMases. Three 
different SMases are available in eukaryotic cells: secreted SMase, acid SMase and neutral SMase. 
Only a particular isoform of neutral SMase, the nSMase2, works at the PM level.  
In addition, the β-galactosidase and the β-glucosidase act at the cell surface. In particular, two 
different β-glucosidase have been detected; GCase which works in the lysosome and a non-
lysosomal β-glucosylceramidase (NLGase).  
NLGase, like GCase, is involved in the degradation of GlcCer to glucose and ceramide. It is 
considered a central enzyme in the glycosphingolipids homeostasis. NLGase is not localized in the 
lysosome but it is strongly associated with the PM, with five possible transmembrane domains. 
The most powerful inhibitor of GBA2 is N-5-adamantane-1-yl-methoxypentyl) deoxynojirimicin 
(AMP-DNM), followed by miglustat [118].  
NLGase is ubiquitously distributed in several tissue and cell lines, in particular it is expressed in 
brain, heart, skeletal muscle, kidney and placenta. In minor part it is detectable in spleen, liver, 
small intestine and lung [119-121], [122]. 
Of particular interest in the context of CF are the enzymes involved in the catabolism of 
sphingolipids, leading to the formation of ceramide and in the regulation of its content at the PM 
level, considering the particular role of glycosphingolipids in the formation of specific PM portions 
called “lipid rafts” which allow to organize the correct microenvironment of several PM proteins 
including CFTR. 
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Figure 11: Representation of sphingolipid metabolism occurring at the cell surface [105]. 
 
Biochemical role of sphingolipids 
 
Several evidences in literature suggest that lipids are not merely a structural component of cell 
membrane but they are also fundamental players of cell signaling and regulatory pathways [123], 
[124, 125].  
Ceramide, ceramide-1-phosphate, sphingosine, and sphingosine-1-phosphate (S1P) have been 
shown to be involved in the regulation of a number of cellular events such as proliferation, 
differentiation, motility, growth, senescence, and apoptosis [126]. Ceramide and S1P have been 
proposed to have opposite roles in these processes. The balance between ceramide and S1P, 
which are metabolically interconnected, determines the entrance into one or more of these 
pathways. 
Complex GSLs are also involved in cell physiology by acting as antigens, mediators of cell adhesion, 
binding agents for microbial toxins and growth factors, and modulators of signal transduction 
[127, 128]. In particular, as said before, SLs together with cholesterol, saturated phospholipids and 
a specific pool of proteins organize macromolecular complex at the cell PM called lipids rafts. The 
lipids rafts theory was postulated on the basis of the spontaneous lateral segregation of 
sphingolipids. This definition was subsequently modified to introduce the notion that lipid rafts 
correspond to membrane areas stabilized by the presence of cholesterol within a liquid-ordered 
phase [129]. 
Nowadays, different studies describe membrane rafts as a dynamic nanoscale domain enriched in 
sphingolipids, cholesterol and gangliosides, which have several roles in cell signal transduction 
[130]. 
Introduction 
29 
 
The complex processes that control the formation and dynamics of lipid rafts are not completely 
understood yet, but one of the most important point is that the saturated hydrocarbon chains in 
cell SLs allows cholesterol to be tightly interacted [86]. 
Lipids rafts are mainly studied taking advantage of their resistance to solubilization by non-ionic 
detergent, such as Triton X-100 and Brij-96. Detergent-resistant membrane (DRM) complexes float 
to low density during sucrose gradient centrifugation and are enriched in rafts proteins and lipids, 
providing a simple means of identifying possible rafts component [86]. 
Probably, in lipid rafts, SLs modulate the functional features of several membrane proteins by 
lateral interactions between SLs and PM proteins, and by short-range alterations of the physico-
chemical properties of the protein membrane microenvironment. Indeed, one of the most 
important property of lipid rafts is that they can include or exclude proteins to variable extents 
[95].  
Proteins with rafts affinity include glycosylphosphatidylinositol (GPI)-anchored proteins, doubly 
acylated proteins, such as Src-family kinases or the α-subunits of heterotrimeric G proteins, 
cholesterol-linked and palmitoylated protein and transmembrane proteins.  
The reasons why some transmembrane proteins are included in lipid rafts is not clear, but some 
evidences suggest that the amino acids in the transmembrane domains near the exoplasmic leaflet 
are critical as well as specific post-translational modification like palmitoylations or 
myristoylations. In addition, a monomeric transmembrane protein may have a short residence 
time in rafts, but when the same protein is crosslinked or oligomerized, its affinity for rafts 
increases.  
The distribution of lipid rafts over the cell surface depends on the cell type. Generally, they are 
more abundant at the PM level, but they are also present in the biosynthetic and endocytic 
pathway, as Golgi apparatus and ER. For example, in polarized epithelial cells, as epithelial 
bronchial cells, lipid rafts accumulate in the apical PM. 
Generally, raft binding recruit proteins to a new-environment, where the phosphorylation state 
can be modified by local kinases and phosphatases, resulting in downstream signaling. Nervous 
system provides many examples of lipid rafts associated signaling. One example is represented by 
GDNF signaling. The glial-cell-derived neurotrophic factor (GDNF) family of ligands is important for 
the development and maintenance of the nervous system. GDNF binds to a multicomponent 
receptor complex that is composed of GPI-linked GDNF receptors-α (GFR-α) and the trans-
membrane tyrosine kinase, RET. The receptor subunit GFRα and RET are not associated with each 
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other in the absence of ligand. However, after extracellular GDNF stimulation, RET moves into 
rafts, where it associates with GFRα in lipid rafts.  
CFTR has been detected in a detergent-resistant membrane fraction prepared from airway 
epithelial cells, suggesting that it may partition into cholesterol-rich membrane microdomains 
(lipid rafts), its compartmentalization has not been demonstrated in intact cells and the influence 
of microdomains on CFTR lateral mobility is unknown [34]. 
Gangliosides, including GM1, contribute to cluster β1-integrin in the membrane [35]. This study, in 
particular, shows that CFTR-silenced cells had a 60% decrease in the glycosphingolipid GM1, 
reduced β1-integrin activation, and decreased phosphorylation of FAK and CAS. The addition of 
GM1 to CFTR-silenced cells was able to restore β1-integrin activation and phosphorylation of FAK 
and CAS to control levels. GM1 supplementation enhanced also the migration of CFTR-silenced 
cells, although it did not fully restore the migration rate to the levels observed in controls. These 
findings suggest that a reduction in GM1 in CFTR-silenced cells contributes to delayed wound 
repair in these cells via inhibition of β1-integrin activation and signaling.  
 
Sphingolipids in Cystic Fibrosis 
 
Lung Sphingolipids 
A complex pattern of SLs characterizes human lung tissue. Globosides, including globotetraosylCer 
and globotriaosylCer, are the major class of neutral glycolipids, followed by LacCer, GlcCer and 
tetrahexosylCer. In addition, among sialylated GLSs, in the lung fourteen different types of 
gangliosides are present. The most abundant is GM3 followed by GM1, disialo GD3, and 
trisialosyllactosylCer GT3 [131, 132]. 
The regulation of ceramide levels is important for lung homeostasis maintenance. Different 
studies reported the involvement of Cer in pulmonary infection, driven by a wide range of 
pathogens including Neisseria gonorrhoeae, Neisseria meningitidis, Staphylococcus aureus, 
Pseudomonas aeruginosa, Listeria monocytogenes, Salmonella typhimurium, Escherichia coli, 
mycobacteria, measles virus, rhinovirus, and sindbis virus [133]. 
Cer is suitable to manage bacterial and viral infection thanks to its biophysical properties. Cer is 
characterized by high hydrophobicity, low amphiphilicity and is able to create small Cer-enriched 
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membrane domain thanks to hydrophobic interaction. Indeed, it is reported that, different stimuli, 
including bacterial infections, are responsible for the creation of Cer-enriched platforms [134]. 
 
Sphingolipids involvement in Cystic Fibrosis lung disease and infection 
Large amount of pro-inflammatory mediators, such as interleukin-8 (IL-8), IL-6 and tumor necrosis 
factor (TNF)-α characterize the airways of CF patients. This condition causes the recruitment of 
neutrophils, unable to eliminate bacteria, leading to an amplification of inflammation and 
perpetual infection. 
Bacterial components bind different receptors, expressed on epithelial cell surface, such as Toll 
like receptors 2, 4 and 5. This binding activates a series of kinases leading to the nuclear 
translocation of transcription factor and expression of pro-inflammatory genes. 
As regards the involvement of SLs in CF lung infection, some studies reported that GSLs belonging 
to the cell surface of epithelial cells could operate as receptor for microorganism. In particular, for 
P. aeruginosa. Indeed, it has been shown that some clinically strains of this bacterium are able to 
bind asialo-GM1 and asialo-GM2. 
Conversely, the role of Cer in CF inflammation and infection is under debate. For instance, 
Guilbault and colleagues demonstrated that plasma of CF patients displays significantly low levels 
of several Cer species. In particular, they found in C57BL/6-CFTR mice an overall reduction of Cer 
level in lung, plasma, ileum and pancreas compared with WT mice [135]. Vilela and co-workers 
tried to explain the possible molecular mechanism involved in the reduction of ceramide in CF. CF 
tracheal epithelial cells are characterized by a high level of glutathione that could decrease the 
intracellular Cer content through the inhibition of neutral sphingomyelinase. The increased 
activation of the pro-inflammatory transcription factor (NF)-kB, which is responsible for the 
abnormally high inflammatory response in CF, seems to be due to Cer deficiency. In fact, increased 
Cer levels, obtained by treatment of CFTR-deficient tracheal epithelial cells with fenretinide, 
results in an improved ability to control Pseudomonas aeruginosa infection [136] [137, 138]. 
As CFTR-dependent binding of P. aeruginosa and subsequent nuclear signaling appear to be part of 
the normal host response to this pathogen, the mechanisms and pathways need to be better 
elucidated. Lipid rafts have been shown to be involved in numerous signaling pathways, as well as 
in internalization of various microorganisms [139] [140-142]. 
As previously explained, rafts are dependent on the presence of cholesterol [143] and 
sphingolipids such as ganglioside GM1 in the cell membrane [144]. Rafts formation leading to the 
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start of signaling either by the concentration of a low number of appropriate proteins into a high 
local concentration or by exclusion of certain proteins from the microenvironment [145, 146]. 
Therefore, the localization of a protein to lipid rafts is often an indicator that the protein is 
essential for some signaling process. It is hypothesized that CFTR relocates to lipid rafts upon 
infection with P. aeruginosa. In addition, CFTR and GM1 colocalize at the site of P. aeruginosa 
internalization into epithelial cells as demonstrated in the study of Kowalski and colleagues in 
2004 [147]. 
 
CFTR and sphingolipids 
As explained before, literature describes CFTR as a transmembrane protein associated with lipid 
rats. Taking into account this characteristic, it is reasonable to speculate that the stabilization of 
the protein or the modulation of its function is driven by SLs interaction.  
For instance, Hamai et al reported a relationship between CFTR expression and SL synthesis. 
Mutated CFTR or decreased expression leads to an increased SL synthesis and as consequence, an 
increased content of SM, sphingosine and sphinganine at the PM level. In addition, it was 
observed that the lack of CFTR causes an alteration of PM ceramide composition, with an 
increased content of long-chain Cer species. The increased Cer production can be interpreted as a 
cellular response to the PM destabilization. In this context, even the SL synthesis could be a 
compensatory mechanism directed to increase membrane stability [148]. 
Another example is represented by the study of Itokazu and colleagues, which described a direct 
correlation between PM levels of ganglioside GM1 and CFTR expression. CFTR-silenced human 
airway cells show a decreased content of GM1 and a lower β1-integrin signalling, resulting in a 
reduction of cell motility. They demonstrated that the addition of GM1 to this type of cells, 
partially restores cell migration. In addition, they demonstrated that the recovery of CFTR in CFTR-
silenced cells significantly increases GM1 levels. On the other hand, the pharmacological inhibition 
of CFTR in normal cells, decreases GM1 content [35]. These data have implications for the CF 
pathology, where altered SL levels in CF airway epithelial cells is probably involved in a diminished 
process of wound repair.  
Ramu and colleagues published data related to the regulation of CFTR function by the PM micro-
environment. They described that the inhibition of CFTR current is caused by the formation of 
ceramide from SM hydrolysis. The clusterization of CFTR in membrane areas rich in ceramide 
makes more difficult the channel activation by phosphorylation of regulatory domain [149]. 
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This set-up gets worse with the presence of some pathogens, such as Pseudomonas aeruginosa, 
which has a SMase activity that hydrolyses SM in situ, leading to the formation of Cer. The reduced 
CFTR activity caused by P. aerugionosa, is accompanied also by an impaired mucociliary clearance 
and, as consequence, a decreased ability to clear bacteria [150]. 
Ceramide produced by bacterial SMase has an effect on CFTR stabilization even influencing the 
regulation of a scaffolding protein ERM (ezrin/radixin/moesin). The ERM complex regulates 
cytoskeletal PM interaction.  
In particular, Ezrin is important for the CFTR activation because it acts as a PKA-anchoring protein, 
recruiting a PKA to the proximity of CFTR, leading to its activation. Some data reported that 
ceramide promotes ERM dephosphorylation and, as consequence its inactivation, through a 
protein phosphatases.  
Although several findings clearly demonstrated that CF pulmonary disease is characterized by 
altered SL metabolism, unfortunately, the direct involvement of SLs in the pathogenesis of CF lung 
disease is still unclear. 
Future progress in understanding the critical role of SLs in the pathophysiology of CF could open 
new perspectives for the development of alternative SL-based therapeutic strategies to increase 
the CFTR stability and function at the cell PM. 
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The new challenge for the CF therapy is based on the development of small molecules able to 
rescue the function of the mutated CFTR. Many pharmacological agents have been designed to 
increase the surface level of mutated CFTR (correctors), as well as its PM activity (potentiators). 
Deletion of phenylalanine at position 508 (F508del) in CFTR is the most common CF-causing 
mutation. Recently, Orkambi®, a combination therapy that includes a corrector of the folding 
defect of F508del-CFTR (lumacaftor or VX-809) and a potentiator of channel activity (ivacaftor or 
VX-770), was approved for CF patients homozygous for this mutation. However, clinical studies 
revealed that the effect of Orkambi® on lung function is slight and very variable [151], [152], [153]. 
Some in vitro findings suggest that the moderate in vivo effect may be due to an adverse effect of 
VX-770 on the stability of the VX-809-corrected protein at PM level [151], [152], [153].  
Indeed, many factors contribute to PM CFTR stability, including its compartmentalization in PM 
macromolecular complex composed by phospholipids, sphingolipids, with particular regards to 
monosialoganglioside 1 (GM1), and scaffolding proteins such as ezrin and NHERF-1 [154]. 
Interestingly, it has been proved that in bronchial epithelial cells the lack of CFTR in the PM, such 
as in the case of the patients carrying the mutation F508del, is associated with a decreased 
content of GM1 [35]. GM1 is an important bioactive sphingolipid that studies have been reported 
to play an important role in the control of several PM proteins and its correlation with CFTR lets 
speculate on its possible role in the CFTR interactome.  
In addition, a recent work from Chin and colleagues suggests that VX-770 and its derivatives, due 
to their high lipophilicity, interact with the lipid bilayer determining changes in the fluidity that are 
responsible for the destabilization of the VX-809-rescued F508del-CFTR. 
On the basis of these evidence, clearly emerges the necessity to develop new strategies that allow 
to stabilize F508del-CFTR rescued by Orkambi® therapy. On this frame, the main objective of my 
PhD project was to investigate if interventions aimed at modifying the lipid PM composition of CF 
bronchial epithelial cells may allow to stabilize F508del-CFTR rescued upon Orkambi® treatment.  
In particular, due to the peculiar properties of the ganglioside GM1 and of its lack on CF bronchial 
epithelial cells, my studies were mainly focused to investigate on the role of this ganglioside in CF, 
with particular regards to its relationship with CFTR.  
Considering all these aspects, the specific aims of my PhD project were: 
1. To investigate in bronchial epithelial cells line if gangliosides GM1 and CFTR residing in the 
same PM microenvironment. 
Aim of the study 
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2. To analyse the potential effect of the exogenous administration of ganglioside GM1 on the 
PM stabilization and function of F508del-CFTR rescued by Orkambi® treatment.  
3. Evaluate the potential cytotoxicity of the exogenously administered GM1. 
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Materials 
 
All the commercial products show the highest degree of purity. Water for solution preparation 
was prepared by using the purification system Milli-Q (Millipore). Trypsin, EDTA Trypan Blue, 
Trizma base, Glycin, Aprotinin, Albumin, Tween-20, sodium dodecyl sulfate (SDS), NaCl, KCl, 
Na2HPO4, KH2PO4, CH3OH, CH3CH2OH, CHCl3, KOH, HCl, CaCl2, citric acid, acetic acid, D-Glucose, 
BSA, polyisobuthylmethacrylate, O-phenylenediamine, H2O2 were purchased from SIGMA-
ALDRICH®. Eagle’s Minimum Essential Medium (EMEM), fetal bovin serum and sodium pyruvate 
were bought from Euroclone®; Conduritol-β-epoxide (CBE) from Calbiochem® AMP-DNM 
[adamantane-pentyl-dNM; N-(5-adamantane-1-yl-methoxy-pentyl) deoxynojirimycin] was a 
generous gift by Prof Aerts of Leiden University; DC Protein Assay by Bio-Rad®. The fluorigenic 
substrates 4-methylumbelliferyl-β-D-glucopyranoside (MUB-β-Glc), 4-methylumbelliferyl-β-D-
galactopyranoside (MUB-β-Gal), 4-methylumbelliferyl n-acetyl-β-d-glucosaminide (MUG), were 
purchased from GlycosinthTM, 6-Hexadecanoylamino-4-methylumbelliferyl phosphorylcholine 
(HMUB-PC) Moscerdam. Disposable flasks for cell culture of 25 cm2 and 75 cm2, 96 multi-well and 
Petri plates (Ø 100, 60, 35 mm), penicillin/streptomycin, and glutamine were bought from 
Euroclone®; the 96 microplate with black bottom from PerkinElmer®; PVDF membranes from GE 
Healthcare Life Sciences; the HPTLC plates and Triton X-100 from Merck MilliporeTM.  
3H-GM1-N3, [
3H]-GM1, Ceramide (Cer), GlucosylCeramide (GlcCer), LactosylCeramide (LacCer), 
Globotryaosylceramide (Gb3), Sphingomyelin (SM), Phosphatidylethanolamine (PE), 
Phosphatidylcoline (PC), GM3, GD3 are materials produced directly in the laboratory where I 
carried out my PhD project.  
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Methods 
 
Cell models 
WT-CFBE, F508del-CFBE: these cell lines are a generous gift from Gaslini medical Hospital of 
Genova belonging to “Cell line and DNA Biobank from patient affected by Genetic Disease”. 
CFBE41o-, are CF human bronchial epithelial cells characterized by the loss of CFTR expression; 
WT-CFBE, F508del-CFBE were stably transfected with the same lentiviral vector, expressing 
respectively WT-CFTR and F508del/F508del-CFTR. The two cell lines grow up into normal plastic 
flasks using Eagle's-minimum essential-medium E-MEM, supplemented with 10% of FBS, 
glutamine (2mM), Penicillin/Streptomycin (100 u/ml and 100 µg/ml respectively), and puromicyn 2 
μg/mL for F508del-CFBE while for WT-CFBE I used the concentration of 0,5 μg/mL. The cells were 
cultured as monolayer in a humidified atmosphere at 37°C and 5% CO2. 
F508del-CFBE-YFP: these cells were a generous gift from the Lab of Dr. Nicoletta Pedemonte, from 
Gaslini Hospital, Genova. The cells were obtained by transfection of F508del-CFBE with the halide-
sensitive yellow fluorescent protein (HS-YFP) YFPH148Q/I152L, as previously reported [155]. 
F508del-CFBE-YFP cells were cultured in the same conditions of F508del-CFBE as reported above 
for the exception of the fibronectin-collagen coating of the growth area of the support. The 
coating solution was composed by: 
- 1 mg of Human Fibronectin resuspended in 10 mL of LHC-Basal medium,  
- 1 ml of bovine collagen type I (30 mg),  
- 100 μL of BSA (1 mg/ml),  
- and LHC-Basal Medium for reaching 100 ml. Finally the above coating solution was filtered with 
filter membrane of 0.2 μm. 
 
Cell treatment with CFTR-modulators 
Ivacaftor (VX-770) and Lumacaftor (VX-809) purchased from Selleckchem, were solubilized in 
DMSO (from Sigma) and were administered directly into the cell’s medium at the final 
concentration of 5 μM; as control, I treated the cells only with the same volume of 
Dimethylsulfoxide (DMSO). 
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Cell feeding with exogenous ganglioside GM1  
GM1 was purified in my laboratory and solubilized in the complete cell culture medium at the final 
concentration of 10, 50 and 100 µM. In particular, appropriate amount of GM1 powder was 
solubilized in methanol in a glass tube, dried under gentle N2 flux, after the total evaporation of 
the solvent, complete cell medium was added and 5 cycles of shaking and sonication were 
performed allowing the complete solubilisation of the ganglioside.  
 
MTT assay 
Cells were plated at the density of 13500 cells/ cm2 in 96-wells microplate, and subjected to the 
different treatment for 6, 12, 24 and 48 hours. After each time-point, the medium was removed 
and the cells were washed with PBS, after the wash I added 71 µL of MTT solution to each well, 
prepared by dissolving thiazolyl blue tetrazolium bromide in PBS at the concentration of 4 mg/ml, 
subsequently they were dissolved in cell culture medium with the ratio of 1:4. The cells were 
incubated for 4 hours in a humidified atmosphere at 37°C and 5% CO2. After that, MTT solution 
was removed and 57 µL of lysis buffer were added (95% isopropanol, 5% formic acid). After ten 
minutes of shaking, the concentration of the formation of formazan salts, was evaluated using a 
microplate reader Victor (Perkin-Elmer), at the wave-length of 570 nm. 
 
Determination of protein content through DC protein assay 
Samples protein content was determined using DC Protein Assay (Bio-Rad), which is based on 
Lowry’s method. The assay was performed in a 96-well microplate using 5 μl of H20 for the 
background, 5 µl containing growing amounts of bovine serum albumin (BSA) for the standards, 
and 5 μl of cell lysates. After sequential addition of 25 μl of reagent A (alkaline solution of copper 
tartrate) and 200 μl of reagent B (dilution of Folin reagent), the microplate was incubated in mild 
agitation for 15 minutes followed by spectrophotometric reading at 750 nm wavelength by a 
microplate reader (Victor, Perkin-Elmer). Protein content was calculated by interpolation of the 
average absorbance value of the sample within the calibration curve built using BSA standards. 
The assay was considered linear in a 0.2-2 mg/ml range. 
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SDS-PAGE and Western Blotting 
The samples were analysed using electrophoresis on a polyacrylamide gel in denaturing 
conditions. The samples were resuspended in Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 
5% 2-mercaptoethanol, 0.01% Bromophenol blue, 10% glycerol) and boiled for 10 minutes at 
100°C before being analysed. Otherwise, the sample dedicated to the analyses of CFTR were 
resuspended in Laemmli buffer and treated at 40°C for 10 minutes. The electrophoresis run was 
performed using a Miniprotean II unit, produced by Bio-Rad. Proteins from cell homogenates 
sample were separated using a precasted gel with the gradient of 4-20% of poly-acrylamide (Bio-
Rad).  
After electrophoresis separation, proteins were transferred into polyvinylidene difluoride (PVDF) 
membranes, at 200 mA for 3 hours at 4°C with a wet blotting (Mini Transblot Biorad). The transfer 
buffer used is Blotting buffer (25 mM Tris-HCl, 192 mM glycine, 15 % methanol, pH 8.0-8.5) Briefly, 
after the transfer the PVDF membrane were incubated in 5% skim milk in TBS-T 0,01% buffer (1 
mM Tris-HCl pH 8, 150 mM NaCl, 0.01% Tween) to block the aspecific binding sites of the 
membrane. Then the PVDF was then washed three times with TBS-T 0.01% and incubated for 1 
hour at room temperature (RT), membranes were incubated overnight at 4°C with the appropriate 
primary antibodies diluted in 5% skim milk in TBS-T 0,01% buffer or in 5% bovine serum albumin 
(BSA) in TBS-T 0,01%. CFTR antibody, purchased from the Cystic Fibrosis North American 
Foundation, was used at the final dilution of 1:2000; Caspase 3, Cyclin-d2 (Cell Signaling), were 
used at the final dilution of 1:1000; EBP50 (NHERF-1), ezrin and p-ezrin antibodies (BD sciences) 
were used at the final dilution of 1:500. 
After washing with TBS-T 0,1%, the PVDF was incubated for 1 hour at RT with secondary 
antibodies resuspended in 5% skim milk in TBS-T 0,1 % or in 5% BSA in TBS-T 0,1%. The Calnexin 
antibody (BD sciences) was used at the final dilution of 1:1000. GAPDH antibody (Sigma) was used 
at the dilution of 1:7000 and β-actin antibody (Cell signalling) was used at the dilution of 1:1000. 
The membrane was then washed again for three times and the peroxidase activity was assessed 
through incubation with a non-radioactive light emitting substrate for the detection of 
immobilized specific antigens conjugated with horseradish peroxidase-linked antibodies (Westar 
Cyanagen) for 1,5 minutes. The signals were revealed using a Mini HD9 (UviTec, Cambridge) and 
analyzed by Nine Alliance mini HD9 software.  
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Cell feeding with [1-3H]-GM1 
The [1-3Hsph]-GM1 was administered to the cells plated in petri plate at the concentration of 90 
nM (corresponding to 0,09 µCi for each plate). Briefly, [1-3Hsph]-GM1 dissolved in methanol was 
transferred into a sterile glass tube and dried under a nitrogen stream, and [1-3H]-GM1 was 
solubilized in an appropriate volume of pre-warmed (37° C) medium (E-MEM). 
The correct solubilisation was verified by measuring the radioactivity associated with an aliquot of 
medium by using beta-scintillator. 
After different time-points, (12, 24 and 48 hours), cells were collected and were used to perform 
the analysis of radioactive lipids. Briefly, cells were lyophilized and subjected to lipid extraction.  
Total lipids from lyophilized cells were extracted with CHCl3:CH3OH:H2O 20:10:1 by vol, followed 
by a second extraction with CHCl3:CH3OH 2:1 by vol. The radioactivity associated with the total 
lipid extract, was evaluated by liquid scintillations using beta-counter system.  
[3H]SLs of total extracts were separated by high performance thin layer chromatography (HPTLC) 
using the solvent system CHCl3:CH3OH: aqueous solution of 0.2% CaCl2 50:42:11 by vol. [
3H]-SLs 
were identified by digital autoradiography using TRacer system (Biospace Lab) and quantified by 
M3vision software. The lipids identification was performed using purified radioactive standards 
[156].  
 
Evaluation of the lipids pattern 
Lipids from the lyophilized samples were extracted with chloroform:methanol:water 20:10:1 
(v:v:v) and subjected to a two-phase Folch’s partitioning to obtain the aqueous (AP) and the 
organic phases (OP) [157]. Briefly, 1550 μL of the solvent system were added to the lyophilized 
samples. The samples were then mixed at RT for 15 minutes and centrifuged at 16.000 x g, for 10 
minutes at RT. The supernatant was collected as total lipid extract (TLE) and the extraction was 
repeated again by adding the solvent system to the pellets. The pellets were air dried and 
resuspended in 1 N NaOH and incubated overnight at RT and then NaOH was diluted to 0.05 N for 
the determination of the protein content with DC assay. 
Aliquots of the TLE were then subjected to phase partitioning adding 20% of water by volume. The 
samples were then mixed at RT for 15 minutes and centrifuged at 16.000 x g, for 15 minutes at RT. 
The AP was recovered, and an equivalent volume of CH3OH:H2O 1:1 (v:v) was added to the organic 
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phase and processed as described before in order to recover all cell gangliosides in AP fraction. 
The aqueous phases were dried under N2 flux, and resuspended in water before undergoing 
dialysis and lyophilization. The organic phases were dried under N2 flux and resuspended in a 
known volume of chloroform:methanol 2:1. Aliquots of the organic phases were then subjected to 
alkaline treatment to remove glycerophospholipids. Alkaline treatment allows to remove 
glycerophospholipids from the organic phases, breaking their ester bonds, and maintaining the 
amide linkage of sphingolipids unaltered. Aliquots of organic phases were dried under nitrogen 
flow and the residue was resuspended with 100 μl of 0,6 M NaOH in methanol and incubated at 
37°C for three hours and overnight at RT. The reaction was blocked by adding 120 μl 0,5 M HCl in 
methanol. Finally, after phase separation (by adding 1.050 μl of chloroform:methanol:water 
70:18:17 by vol), the new organic phases were used for TLC analysis. [157] 
 
Thin layer chromatography 
To determine endogenous lipid content, the various samples were analysed by monodimensional 
silica gel HPTLC using different solvent systems. The lipids contained in OP and MetOP were 
separated using a solvent system composed by chloroform:methanol:H2O 110:40:6 (v:v:v) and 
visualised with anisaldehyde reagent, whereas for AP chloroform:methanol:0.2% aqueous CaCl2 
50:42:11 (v:v:v) were used and GM1 was revealed by immunostaining with cholera toxin. 
Glycerophospholipid pattern was determined on OP using the solvent system: 
chloroform:methanol:acetic acid:water 30:20:2:1 (v:v:v:v) and it was visualised with phosphorous 
reagent. Cholesterol content was evaluated on MetOP using exane:ethyl acetate 3:2 as solvent 
system and it was visualised with anisaldehyde reagent. The lipids were identified by the 
comigration on the same HPTLC of authentic standards.  
 
TLC immunostaining with cholera toxin 
Cholera toxin binding to GM1 was assessed by TLC immunostaining following standard protocols 
[158]. Briefly, after chromatographic separation (as described above) the TLC plates were coated 
with a polyisobuthylmethacrylate solution [157], three times, and air dried for 1 hour before being 
immersed in blocking solution (3% BSA in PBS) for 1 hour. The plates were then incubated with 
cholera toxin at 10 μg/mL in 1% BSA in PBS for 1 hours at RT. After the incubation, two washes 
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with PBS were performed and the immunoreactive bands were revealed using o-
phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. 
 
Photolabelling experiment 
[1-3H]-GM1-N3 is a radioactive and photoactivable GM1 derivative. In particular, 
3H-GM1-N3 is 
radioactive on sphingosine and carries a photoactivable group at the terminal portion of the fatty 
acid. As photoactivable group, I used the azide linked to nitrophenyl which is very sensitive to light 
and it must be handled with care in dark conditions (i.e. under red safelight). 
[1-3H]-GM1-N3 was administered at the concentration of 1.25 µM in presence of the same amount 
of normal GM1. Briefly, under dark conditions, the appropriate amount of [1-3H]-GM1-N3 
dissolved in 2-propanol was transferred into a sterile glass tube and dried under a nitrogen 
stream. After that, [1-3H]-GM1-N3 was solubilized in an appropriate volume of pre-warmed (37° C) 
medium (E-MEM) and administered to the cells previously plated in petri plate and subjected to 
different treatments. After six hours in dark conditions, the medium was collected and its 
radioactivity was evaluated. The cells were washed with medium containing FBS, for 30 minutes 
and then with PBS containing Na3VO4. Finally, the cells were illuminated with UV lamp for 40 
minutes. After this, the cells were collected in PBS containing Na3VO4, and lysed to performed the 
SDS-PAGE analysis. 
 
Enzymatic activity associated with cell lysate  
The enzymatic activities of β-Glucocerebrosidase (GCase), non lysosomal β-glucosylceramidase 
(NLGase), β-Galactosidase (β-Gal), β-Hexosaminidase (β-Hex), and sphingomyelinase (SMase) in 
the total cell lysates were determined using fluorigenic substrates as described by Aureli and 
colleagues, with few modifications [159, 160] 
Briefly, cells were washed twice with PBS and were harvested and suspended in water in the 
presence of a protease inhibitor cocktail (Sigma-Aldrich). Total cell protein content was evaluated 
by DC protein assay (Biorad) according to manufacturer instructions.  
Equal amount of cell proteins were transferred into a 96-well microplate and the assay was 
performed three-fold in replicate. MUB-Glc was solubilized in McIlvaine buffer (pH 6) at the 
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concentration of 24 mM. MUB-Gal, MUG and H-MUB-PC were solubilized in McIlvaine buffer (pH 
5.2) at the concentration of 250 µM, 2 mM and 100 µM respectively.  
For GCase and NLGase assays, cells were pre-incubated for 30 minutes at RT with 5 nM AMP-dNM 
[adamantane-pentyl-dNM; N-(5-adamantane-1-yl-methoxy-pentyl) deoxynojirimycin] and 1 mM 
Conduritol B Epoxide (CBE) respectively. 
The reaction mixtures were incubated at 37°C under gentle shaking. After transferring 10 μl of the 
reaction mixtures to a 96 black well microplate and adding 190 μl of glycine (0.25M, pH 10.7), the 
obtained fluorescence was detected at different time points by a Victor microplate reader (Perkin 
Elmer), (MUB: λex: 355 nm /λem: 460nm; H-MUB: λex: 405 nm /λem: 460nm) after adding 190 µl of 
0.25 M glycine (containing 0,3% Triton X-100 for SMase assay), pH 10.7. 
Standards free MUB and H-MUB were used to set the calibration curves in order to quantify the 
substrates hydrolysis. 
The enzymatic activity was expressed as pmol of product on mg protein per hour.  
 
Enzymatic activity associated with cell plasma membrane 
The assay, used during my experiments, allows the detection of the PM associated enzymatic 
activity directly on living cells, using fluorigenic substrates. This method is based on the 
observation that the fluorigenic substrates commonly used for the in vitro assay of glycohydrolase 
activities are not taken up by living cells [161]. 
Indeed, under the appropriate experimental conditions, it is not possible to observe any 
fluorescence associated with cells. Moreover, the artificial substrates did not undergo to 
spontaneous hydrolysis or to hydrolysis driven by secreted enzymes. Thus, their hydrolysis under 
these experimental conditions is due exclusively to the PM-associated enzymatic activities [162].  
PM associated activities of β-Galactosidase (β-Gal), β-Glucocerebrosidase (GCase), non lysosomal 
β-glucosylceramidase (NLGase), β-Hexosaminidase (β-Hex) and sphingomyelinase (SMase) 
activities were determined on living cells, plated in 96-well microplate at density of 20000 
cells/well, by a high throughput assay.  
For GCase and NLGase assays, cells were pre-incubated for 30 minutes at RT in DMEM-F12 with 5 
nM AMP-dNM [adamantane-pentyl-dNM; N-(5-adamantane-1-yl-methoxy-pentyl) 
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deoxynojirimycin] and 1 mM CBE respectively [163] and then incubated with MUB-Glc solubilized 
in DMEM-F2 pH 6.2 at the final concentration of 6 mM. β-Gal, and β-Hex activities were assayed 
using the artificial substrates MUB-Gal and solubilized in DMEM-F12 without phenol red at pH 6, 
at the final concentrations of 250 µM and 2 mM respectively. SMase activity was assayed using the 
artificial substrates 6-hexadecanoylamino-4-methylumbelliferyl-phosphoryl-choline (H-MUB-PC) 
solubilized in the same DMEM-F12 at the final concentration of 100 µM. At different time points 
aliquots of medium (10 µl) were analyzed by fluorimeter in a microplate reader (Victor, Perkin 
Elmer) (MUB: λex: 355 nm /λem: 460nm; H-MUB: λex: 405 nm /λem: 460nm) after adding 190 µl of 
0.25 M glycine (containing 0,3% Triton X-100 for SMase assay), pH 10.7. 
Standards free MUB and H-MUB were used to set the calibration curves in order to quantify the 
substrates hydrolysis. 
The enzymatic activity was expressed as pmol of products on 106cells, per hour. 
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Study of CFTR function using video-live image microscopy 
The following experiments were carried out in collaboration with Dr. Anna Tamanini from the 
Department of Pathology of Verona University Hospital.  
 
F508del-CFBE-YFP cells were plated on sterile glass coverslips in complete medium (diameter 24 
mm, thickness 0.13-0.17 from VWR International, West Chester, Pennsylvania, USA) previously 
coated with Fibronectin-Collagen as described above. In particular, 30x106 cells were plated for 
each coverslip in order to reach the 80% of confluence after 48 hours at the time of the 
incubation.  
The day after seeding, the F508del-CFBE-YFP cells were treated with CFTR-modulators and 
ganglioside GM1 as previously described. 
After 48 hours treatment, the culture medium was removed and the cells were washed two times 
with Dulbecco’s PBS (137 mM NaCl, 2,7 mM KCl, 8,1 mM Na2HPO4, 1,5 mM KH2PO4, 1 mM CaCl2, 
0.5 mM MgCl2) and after this, they were incubated with stimulation cocktail (Forskolin + VX-770 in 
Dulbecco’s PBS) or inhibition cocktail (CFTR Inhibitor-172 in Dulbecco’s PBS) for 30 minutes. After 
that, cells were washed with Dulbecco’s PBS and the coverslips were transferred into a 
thermostatically controlled perfusion chamber of the microscope, to maintain the cells alive and in 
their physiological conditions. 
The microscope used was Nikon TMD inverted microscope with a Nikon Fluor 40 objective. The 
signal was acquired with a Hamamatsu C2400–97 charge-coupled intensified video camera at a 
rate of 1 frame/3 s. Fluorescence coming from each single cell was analyzed by customized 
software (Spin, Vicenza, Italy). Results are presented as transformed data to obtain the percentage 
signal variation (Fx) relative to the time of addition of the stimulus, according to the equation: Fx 
([Ft- Fo]/Fo) 100, where Ft and Fo are the fluorescence values at the time t and at the time of 
addition of iodide, 20 respectively. 
 
Statistical analysis 
All the experiments were performed in triplicate and statistical significance was determined by 
Student-Neumann-Keuls post hoc test (comparison between two groups) and for more than two 
groups by one-way or two-way ANOVA (followed by Turkey or Dunnett Neueman-Keuls on 
Bonferroni post test), with p <0.05 as significant. 
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Overexpression of F508del-CFTR induces alteration of the lipid composition in 
cystic fibrosis bronchial epithelial cells CFBE 
 
CF, the most common genetic disease, caused by mutations in the CFTR gene, affects several 
organs, with major complications observed in the lung. Indeed, the major cause of morbidity and 
mortality in CF patients is respiratory failure secondary to pulmonary infections and inflammation. 
In the lung of CF patients, the lack of CFTR is responsible for secondary alteration especially in the 
physiology of the bronchial epithelial cells that contributes to aggravates the phenotypical 
manifestation of the disease. 
Recent data from literature show that the reduced content of CFTR at PM in CFTR-silenced cells is 
followed by a decreased content of ganglioside GM1 [35]. GM1 is an important bioactive lipid 
involved in the organization of macromolecular complex belonging to PM, called lipid rafts.  
Interestingly, it has been demonstrated that CFTR is associated with this particular membrane 
structure and that only a precise coordination between the lipids and CFTR-scaffolding proteins 
allow CFTR to exert its main function. In particular, just the loss of only one among the 
components, could compromise the formation of the entire complex and could be at the basis of 
the incapability of the current CF therapy to stably restore the function of F508del-CFTR.  
Based on these considerations, the main aim of my PhD project was to investigate the possible 
role of the ganglioside GM1 on the CFTR PM stabilization and function. To this purpose, I first need 
to select the suitable cellular model which can mimic physiological feature of CF and non-CF 
bronchial epithelial cells. 
One of the more used in vitro model of CF bronchial epithelial cells, is represented by the 
CFBE41o- cell line: these cells have lost CFTR protein expression and so they represent the 
appropriate cellular model on which induce the stable expression of:  
I) the WT form of CFTR to have a control cell line (WT-CFBE) and  
II) the F508del-CFTR to have the pathological counterpart with the same genetic background 
(F508del-CFBE).  
To do this, CFBE41o- cells were transfected with a lentiviral vector for the expression of WT-CFTR 
or F508del-CFTR; these cell lines are cultured with the same medium, E-MEM added up with the 
selecting antibiotic puromycin. 
Using these cell lines, I firstly performed lipid analysis by thin layer chromatography. The cells 
were collected at the 80% of confluence, lysed and lyophilized. Lipids from the lyophilized samples 
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were extracted with a solvent system composed of chloroform:methanol:water 20:10:1 (v:v:v) and 
subjected to a two-phase Folch’s partitioning to obtain the aqueous (AP) and the organic phases 
(OP). Aliquots of the organic phase were then subjected to alkaline treatment to remove 
glycerophospholipids (MetOP) [157]. Aliquots of AP, OP and MetOP corresponding to the same 
amount of cellular proteins of each cell lines, were loaded on a plate for thin layer 
chromatography and the lipids were then separated by using different solvent systems and 
visualized by specific reagents.  
As shown in figure 12, F508del-CFBE cells revealed differences in gangliosides composition; in 
particular, GM1 seems to be slightly decreased while ganglioside GM3 was significantly higher 
with respect to WT-CFBE cells. From the analysis of neutral lipids, the most significant difference 
was represented by lactosylceramide, which was abundant in WT-CFBE cells and scantly 
detectable in the pathological counterpart. I also analysed cholesterol content and as shown in 
panel C, F508del-CFBE cells are characterized by a reduced content of cholesterol with respect to 
WT-CFBE cells.  
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Figure 12: Lipid composition of WT and F508del-CFBE cells 
Cells lysates from CFBE overexpressing WT or F508del-CFTR were subjected to lipid extraction with 
CHCl3:CH3OH:H2O 20:10:1 (v:v:v). Total lipid extracts were further subjected to a two-phase partitioning 
resulting in the separation of an aqueous phase (AP) containing gangliosides and in an organic phase (OP) 
containing all other lipids. Aliquots of the organic phases were then subjected to alkaline treatment to 
remove glycerophospholipids (MetOP). 
(A): ganglioside pattern were evaluated loading TLC with a volume of AP equivalent to 700 µg of cell lysate. 
Lipids were separated using the solvent system CHCl3:CH3OH:0,2% aqueous solution of CaCl2 50:42:11 (v:v:v) 
and visualized by Earlich reactive. 
(B): neutral lipids were evaluated loading TLC with a volume of MetOP equivalent to 500 µg of cell lysate. 
Lipids were separated using the solvent system CHCl3:CH3OH: H2O 110:40:6 (v:v:v) and visualized by 
anisaldehyde reagent.  
(C): cholesterol was evaluated loading TLC with a volume of MetOP equivalent to 300 µg of cell lysate. Lipids 
were separated using the solvent system Hexane: Ethyl Acetate 3:2 (v:v) and visualized by anisaldehyde 
reagent.  
GlcCer: glucosylceramide; LacCer: Lactosylceramide; SM: sphingomyelin; GM1: ganglioside, Gb3: 
Globoatriosylceramide; chol: Cholesterol 
 
To further confirm the modifications in the cellular content of GM1, I performed an 
immunostaining analysis with cholera toxin because of the high affinity of its subunit β for the 
above said ganglioside. After separation with thin layer chromatography, which was performed in 
the same conditions used before for the gangliosides analyses, the plate was incubated with the β-
subunit of cholera toxin HRP-conjugated and then the signal was revealed using o-
phenylenediamine. 
As shown in figure 13, the immunostaining with cholera toxin revealed a decreased content of 
GM1 in F508del-CFBE cells of about ~ 40% with respect to WT-CFBE cell line.  
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Figure 13: GM1 levels in CFBE cells over-expressing wild type and F508del-CFTR 
(A): TLC immunostaining with cholera toxin: briefly, TLC was loaded with aqueous volume equivalent to the 
same amount of total cell protein (150 µg each). After chromatographic separation with solvent system: 
CHCl3:CH3OH:0,2% aqueous solution of CaCl2 50:42:11 by vol., TLC plates were fixed with a 
polyisobuthylmethacrylate solution, air dried and incubated with 3% BSA in PBS for 1 hour. Plates were then 
incubated with cholera toxin at the concentration of 10 μg/mL in 1% BSA in PBS for 1 hour at room 
temperature (RT). After washes with PBS the immunoreactive bands were revealed using o-
phenylenediamine (OPD)/H
2
O
2
 in 0.05 M citrate-phosphate buffer pH 5.0.  
(B): Semi quantitative graph of GM1 content in WT and F508del-CFBE cell lines obtained by densitometric 
quantification of GM1 positive bands using ImageJ software; the content of GM1 was represented as fold 
increase with respect to WT-CFBE.  
*p<0.05 vs WT-CFBE 
 
Taken together these results suggest that in bronchial epithelial cells the expression of F508del-
CFTR induces modifications in sphingolipid composition. 
Evidences in literature proved that mutations in CFTR affects also the endo-lysosomal 
compartment which is one of the main cellular districts involved in the SLs catabolism. I evaluated 
the effect of the overexpression of F508del-CFTR on the main hydrolases involved in the 
sphingolipid catabolism. In particular, I evaluated the enzymatic activities of β-glucocerebrosidase 
(GCase), non lysosomal β-glucosylceramidase (NLGase), β-galactosidase (β-gal), β-hexosaminidase 
(β-hex), and sphingomyelinase (SMase) by an in vitro assay based on the use of fluorigenic 
substrates as described by Aureli and colleagues, with few modifications [159], [160]. 
Interestingly, this analysis revealed some differences in the hydrolases activity (figure 14). In 
particular the activity of GCase, NLGase, β-gal, SMase were increased respectively of 3, 1.5, 2, and 
2.5 fold in F508del-CFBE with respect to WT-CFBE cells. No differences were detected for β-hex. 
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Figure 14: Hydrolases activity associated with total cell lysate of WT and F508del-CFBE cell lines 
The measurement of the hydrolases activity was conducted on cell lysates using an in vitro assay based on 
artificial fluorigenic substrates. The enzymatic activity was expressed as pmoles of product on mg of 
proteins per hour.  
GCase: β-Glucocerebrosidase; NLGase: Non lysosomal β-Glucosylceramidase; β-gal: β-galactosidase; β-hex: 
β-hexosaminidase; SMase: Sphingomyelinase 
*p<0.05 vs WT-CFBE 
 
It is nowadays demonstrated the existence of a crosstalk among the lysosomal enzymes and the 
counterpart associated with the PM. For this reason, I subsequently measured the enzymatic 
activities of the same hydrolases but using an assay that allow to detect the activity only of the 
enzymes associated with the cell surface. 
As result, I found that F508del-CFTR cells were characterized by 1.5 fold increase in GCase and 
NLGase, whereas the activity of β-hex and SMase decreased of about 2 fold with respect to WT-
CFBE cells. No changes were found in the activity of PM β-gal (figure 15).  
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Figure 15: Hydrolases activity associated with the cell plasma membrane of WT and F508del-CFBE cell 
lines 
The measurement of the plasma membrane hydrolases activities were conducted on living cells, using 
artificial fluorigenic substrates. The enzymatic activity was expressed as pmoles of product, on 106 cells per 
hour.  
GCase: β-Glucocerebrosidase; NLGase: Non lysosomal β-Glucosylceramidase; β-gal: β-galactosidase; β-hex: 
β-hexosaminidase; SMase: Sphingomyelinase 
*p<0.03 vs CFBE 
 
Taken together these results indicate that the expression of F508del-CFTR induces in bronchial 
epithelial cells changes in the sphingolipids composition and in their catabolism both intracellularly 
and at the PM level. In addition, This result confirm the validity of WT-CFBE and F508del-CFBE cell 
lines as experimental model to study the relationship between CFTR and PM sphingolipids.  
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The chronic treatment of F508del-CFBE cells with potentiator VX-770 reverts the 
effect of the corrector VX-809 in terms of F508del-CFTR maturation, CFTR 
scaffolding protein content and lipid composition 
 
Nowadays the new therapeutic strategies for the treatment of CF are focused on restoring 
mutated-CFTR function. Indeed, small molecules that are able to restore mutated-CFTR function 
have recently been developed. The first small molecule enrolled in a clinical trial was the 
potentiator VX-770 Ivacaftor (Kalydeco®, Vertex Pharmaceuticals). The drug was able to increase 
chloride transport by potentiating the channel-open probability (or gating) of the G551D-CFTR 
protein. Ivacaftor has been approved by the US Food and Drug Administration (FDA) and European 
Commission for the treatment of CF in patients aged ≥ 6 years who have the G551D mutation in 
the CFTR gene [164]. Unfortunately, the mutation G551D includes only the 2% of CF patients, 
while the most common mutation is the F508del, which affects around the 75% of Caucasian 
population. F508del mutation affects not only the open state of the channel but also its folding in 
the ER, for this reason the use of the only VX-770 is not enough to restore its activity. 
The challenge was the development of a molecule which could drive protein folding, to this aim it 
has been developed the corrector VX-809, Lumacaftor a drug able to correct mutated-CFTR 
increasing its targeting to the cell PM. The therapeutic strategy followed for CF patients carrying 
F508del was the combined treatment with Lumacaftor and Ivacaftor called with the commercial 
name of Orkambi®. Despite an improvement of F508del-CFTR activity upon an acute treatment, 
during the chronic treatment Orkambi® loose its beneficial function suggesting an instability of the 
channel at the cell surface.  
Interestingly, in vitro studies suggested that VX-770 contributes to F508del-CFTR destabilization at 
the PM level by an interaction with the lipid environment of CFTR. 
To further investigate this issue, I evaluated the effect of VX-770, VX-809 and of their combination 
on F508del-CFTR cells in terms of F508del-CFTR maturation, CFTR content, scaffolding proteins 
ezrin and NHERF-1, and on lipid composition.  
F508del-CFBE cells were treated for 48 hours with 5µM of VX-770, and VX-809 alone or in 
combination. After the incubation, I analysed CFTR maturation by using SDS-PAGE and Western 
Blot technique with a specific antibody against CFTR. 
As shown in figure 16, untreated F508del-CFBE cells are characterized by the presence of the only 
immature form of CFTR known as b-band. When the cells were treated with only potentiator VX-
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770, I didn’t observe any change in CFTR maturation. Indeed, when I treated the cells with 
corrector VX-809, it was possible to detect a remarkable maturation of the protein indicated as 
band c. Unfortunately, after treating the cells with both drugs, the positive effect of VX-809 on 
CFTR maturation was completely lost, suggesting a negative effect of VX-770. 
 
 
 
Figure 16: Effect of VX-770 and VX-809 on F508del-CFTR maturation 
Cells overexpressing F508del-CFTR were treated or not for 48 hours with 5 µM VX-770 and/or VX-809. CFTR 
was evaluated by immunoblotting. GAPDH was evaluated as loading control.  
 
After that, I evaluated the effect of the different treatments on the protein levels of CFTR-
scaffolding proteins such as ezrin and NHERF-1.  
As shown in the Western blot reported in figure 17, the treatment of the F508del-CFBE cells with 
corrector VX-809 induced an increase in the protein level of NHERF-1, ezrin and its bioactive form 
p-ezrin, with respect to untreated cells. Instead, when I treated the cells with the potentiator VX-
770, I observed that all of them have significantly decreased, condition preserved also in presence 
of the combined treatment. These data highlight that once again the potentiator seems to have a 
negative effect on F508del-CFTR maturation and in the formation of the interactome that is 
involved in its PM stability and function. 
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Figure 17: VX-770 induces a decrease on content of CFTR scaffolding proteins 
Cells overexpressing F508del-CFTR were treated or not for 48 hours with 5 µM VX-770 and/or 5 µM VX-809. 
NHERF-1, ezrin and p-ezrin were evaluated by immunoblotting. GAPDH was evaluated as loading control.  
 
As above said, CFTR at cell PM needs to have a specific microenvironment, featured by both 
specific lipids and proteins. Since VX-770 compromises the expression of the CFTR-scaffolding 
proteins I evaluated the effects of corrector and potentiator treatment on lipid composition. 
Treated cells were collected, lysed and lyophilised; lipids from the lyophilised samples were 
extracted with chloroform:methanol:water 20:10:1 (v:v:v) and subjected to a two-phase Folch’s 
partitioning to obtain the aqueous (AP) and the organic phases (OP). Aliquots of the organic phase 
were then subjected to alkaline treatment to remove glycerophospholipids (MetOP) as previously 
described. The lipids were then separated by TLC using different solvent systems. 
The analysis of neutral lipids, as shown in figure 18 panel A, indicate that all the treatment induced 
a decrease in the content of globoatriosylceramide with respect to untreated cells. Whereas, the 
potentiator induced a decrease also in the cellular levels of lactosylceramide. I also analyzed the 
phospholipids pattern and as pointed out in figure 18 panel B, I couldn’t observe relevant 
differences between control and treated cells. By the analyses of the cholesterol emerges that in 
presence of VX-770 its cellular content decreased (figure 18 panel C).  
 
Results 
58 
 
 
 
Figure 18: Effect of VX-770 and VX-809 on F508del-CFBE cells 
Cells overexpressing F508del-CFTR were treated or not for 48 hours with 5 µM VX-770 and/or 5 µM VX-809.  
Cells lysates were then subjected to lipid extraction with CHCl3:CH3-OH:H2O 20:10:1 (v:v:v). Total lipid 
extracts were further subjected to a two-phase partitioning resulting in the separation of an aqueous phase 
(AP) containing gangliosides and in an organic phase (OP) containing all other lipids. Aliquots of the organic 
phases were then subjected to alkaline treatment to remove glycerophospholipids (MetOP).  
(A): neutral lipids were evaluated loading TLC with a volume of MetOP equivalent to 500 µg of cell lysate. 
Lipids were separated using the solvent system CHCl3: CH3OH: H2O 110:40:6 (v:v:v) and visualized by 
anisaldehyde reagent.  
(B): phospholipids were evaluated loading TLC with a volume of OP equivalent to200 µg of cell lysate. Lipids 
were separated using the solvent system CHCl3:CH3OH:Acetic Acid: H2O 30:20:2:1 (v:v:v), and visualized with 
phosphorus reactive. 
(C): cholesterol was evaluated loading TLC with a volume of MetOP equivalent to 300 µg of cell lysate. Lipids 
were separated using the solvent system Hexane: Ethyl Acetate 3:2 (v:v) and visualized by anisaldehyde 
reagent.  
GlcCer: glucosylceramide; LacCer: Lactosylceramide; SM: sphingomyelin; Gb3: Globoatriosylceramide; PC: 
phosphatidylcholine, PE: phosphatidylethanolammine, chol: Cholesterol 
 
Moreover, by immunostaining with cholera toxin I evaluated the effect of the drugs treatments on 
the cellular levels of GM1. As it is possible to observe in the image and the relative 
semiquantitative graph reported in figure 19, when the cells were subjected to treatment with 
corrector, potentiator individually or in combination, the GM1 content decreases significantly of 
about 25 -30%.  
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Figure 19: The pharmacological treatment of F508del-CFBE cells with VX-770 and VX-809 reduces the 
levels of ganglioside GM1 
(A): TLC immunostaining with cholera toxin: briefly, TLC was loaded with aqueous volume equivalent to the 
same amount of total cell protein (150 µg each). After chromatographic separation with solvent system: 
CHCl3:CH3OH:CaCl2 50:42:11 by vol., TLC plates were fixed with a polyisobuthylmethacrylate solution, air 
dried and incubated with 3% BSA in PBS for 1 hour. Plates were then incubated with cholera toxin at 10 
μg/mL in 1% BSA in PBS for 1 hour at room temperature (RT). After washes with PBS, the immunoreactive 
bands were revealed using o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. 
(B): Semi quantitative graph of GM1 content in F508del-CFBE cells, obtained by densitometric quantification 
of GM1 positive bands using ImageJ software; the content of GM1 was represented as fold increase respect 
to CTRL.  
*p<0.008 vs CTRL  
 
In conclusion, this set of analysis revealed that potentiator VX-770 seems to be responsible for an 
alteration of CFTR protein and lipid interactome that could be responsible for the destabilization at 
PM of the F508del-CFTR restored by VX-809. 
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GM1 and WT-CFTR are closely associated at plasma membrane level 
 
To further investigate the relationship between CFTR and GM1, with particular regard for their 
possible localization at the same PM domain, I performed photolabelling experiments using a GM1 
derivative tritium labelled on the sphingosine moiety and carring a photoactivable group at the 
end of the fatty acid (figure 20 panel A). The photoactivable group is an azide linked to a 
nitrophenyl moiety. In this configuration the azide group is very sensitive to UV light with λ 360 
nm. Indeed, after UV irradiation the azide is converted to a nitrene group that is very instable 
catalysing three main reactions: addition, insertion, and nucleophilic reactions (figure 20 panel B). 
In these view, the nitrene group can covalently bind the molecules close to the ganglioside, 
making it radioactive and consequently detectable. For this reason, if I detected by digital 
radiography radioactive proteins after the SDS-PAGE separation, I could conclude that these ones 
in their natural environment, were strictly closed to GM1.  
 
 
Figure 20:characteristic of the radioactive and photoactivable GM1 derivative 
(A):Structure of the radioactive and photoactivable GM1 derivative. 
(B):Schematic representation of the reaction catalysed by the nitrene group produced by the UV irradiation 
of the azide. 
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To this purpose, I administered in dark condition (i.e. under red safe light), 3H-GM1-N3 to WT-CFBE 
and F508del-CFBE seeded in petri plates of Φ 100 mm. After 6 hours of incubations, the medium 
contained 3H-GM1-N3 was removed and the cells were washed three times with complete culture 
medium and irradiated in PBS under UV rays for 40 minutes. After that, the cells were harvested 
and proteins were separated by SDS-PAGE.  
First, I analyzed the presence of CFTR by Western blotting analyses. As shown in figure 21, I 
detected in WT-CFBE cells both b-band and c-band of CFTR, whereas in F508del-CFBE cells I was 
able to detect only the immature form of CFTR (b-band). The same PVDF was subsequently 
analysed for the presence of radioactive proteins generated by the crosslink with the 
photoactivable and radioactive GM1. For this reason the PVDF were subjected to digital 
autoradiography using the TRacer instrumentation. The results obtained are reported in figure 21, 
where it is possible to observe in WT-CFBE cells, the presence of a radioactive band correspondent 
to the same molecular weight of the mature form of CFTR, which is the one associated with PM, 
whereas no radioactive signals were detected in F508del-CFBE cells.  
 
 
 
Figure 21: Ganglioside GM1 interacts with CFTR  
CFBE overexpressing the WT and the F508del-CFTR were treated with tracer quantity of 3H-GM1-N3 in dark 
conditions and after 6 hours, cells were illuminated under UV light, harvested and subjected to SDS-PAGE 
and Western Blotting analyses for the detection of CFTR. Subsequently, the same PVDF was subjected to 
digital autoradiography to revealed the radioactivity due to the cross-link between GM1 and neighbouring 
proteins.  
(A): At left immunoblotting analysis of CFTR performed in WT-CFBE cells, at right digital autoradiography of 
the same PVDF.  
(B): At left immunoblotting analysis of CFTR performed in F508del-CFBE cells, at right digital 
autoradiography of the same PVDF. 
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The results of photolabelling experiments proved a remarkable proximity between GM1 and CFTR 
suggesting a direct interaction between them at the cell surface.  
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Ganglioside GM1 is adjuvant to Orkambi®therapy in stabilising F508del-CFTR at 
the plasma membrane 
 
The results obtained so far, suggested a possible direct role of the ganglioside GM1 in the 
stabilization and functional regulation of CFTR at the PM of bronchial epithelial cells. Indeed, the 
expression of F508del-CFTR is paralleled to a decreased content of ganglioside GM1, and the same 
ganglioside seems to have a direct interaction with the WT-CFTR. To further support its active role 
in the CFTR interactome, I exogenously administered the ganglioside to F508del-CFBE cells, using a 
culture medium containing Orkambi®.  
The cells were seeded and treated with 5 μM of both corrector VX-809 and potentiator VX-770, 
and with 10, 50 and 100 μM GM1 for 48 hours. At the end of the incubation, cells were collected, 
lysed, subjected to SDS-PAGE and Western blot analysis to investigate the effect of GM1 and 
Orkambi® on the maturation of F508del-CFTR. 
The results shown in figure 22, indicate that the treatment with GM1 positively influences CFTR 
maturation. Indeed, for all the treatment I could observe an increase of c-band, the mature form, 
with respect to untreated cells. However, the 50 μM GM1 is the concentration that shown the 
highest recovery and for this reason was selected to be used for the subsequent experiments. 
  
Results 
64 
 
 
 
Figure 22: Effect of GM1 administration on F508del-CFTR maturation upon treatment with corrector VX-
809 and potentiator VX-770 
Representative Western-blot images of the content of CFTR performed on F508del-CFBE cells subjected to 
the treatment for 48 hours, with 5 µM corrector VX-809, 5 µM potentiator VX-770 and ganglioside GM1 at 
the concentration of 10, 50 and 100 μM. GAPDH was evaluated as loading control.  
c band: mature and glycosylated form of protein CFTR, inserted in plasma membrane; b band: immature 
form of protein CFTR  
 
After that, I performed immunostaining analyses with cholera toxin to confirm the association of 
GM1 with treated cells. F508del-CFBE cells were treated for 48 hours with 50 μM of GM1, then 
cells were washed many times with fresh medium containing 10% of FBS, to eliminate any trace of 
ganglioside not directly associated with PM, cells were collected, lysed and lyophilized. The 
content of GM1 was evaluated as previously described. The results are shown on figure 23, where 
clearly emerges that the exogenous GM1 was taken up by the F508del-CFBE cells. Indeed, as it is 
possible to observe from the TLC immunostaining (figure 23, panel A) and from the semi-
quantitative graph (figure 23, panel B) the amount of GM1 in the F508del-CFBE cells has notably 
increased of about ~ 3,5 fold, with respect to control untreated cells. 
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Figure 23: Evaluation of GM1 association with F508del-CFBE cells 
F508del-CFBE cells were treated for 48 hours with 50 µM GM1, then were collected for lipid analysis. 
(A): TLC immunostaining with cholera toxin: briefly, TLC was loaded with aqueous volume equivalent to the 
same amount of total cell proteins (150 µg each). After chromatographic separation with solvent system: 
CHCl3:CH3OH:CaCl2 50:42:11 by vol., TLC plates were fixed with a polyisobuthylmethacrylate solution, air 
dried and incubated with 3% BSA in PBS for 1 hour. Plates were then incubated with cholera toxin at 10 
μg/mL in 1% BSA in PBS for 1 hour at room temperature (RT). After washes with PBS the immunoreactive 
bands were revealed using o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. 
(B): Semi quantitative graph of GM1 content in F508del-CFBE cells treated or not with 50 μM GM1, obtained 
by densitometric quantification of GM1 positive bands using Imagej software; the content of GM1 was 
represented as fold increase respect to CTRL.  
*p<0.02 vs CTRL 
 
Furthermore, I investigated the metabolic fate of the exogenously administered GM1. To perform 
this study, I treated F508del-CFBE cells for different time points (up to 48 hours) with 5 μM of 
corrector VX-809, 5 μM of potentiator VX-770, and with 50 μM of the same GM1 used before, 
mixed with trace of GM1 derivative radioactive on the sphingosine moiety (3H-GM1). By the 
analysis of the radioactive lipids, I can evaluate the metabolism of the only administered GM1, 
excluding the contribution of the endogenous counterpart.  
After 12, 24 and 48 hours the cells were collected lysed and lyophilised. Radioactive lipids were 
separated with HPTLC and visualized by digital autoradiography. The results obtained are reported 
in figure 24 and I found that, for each considered time point, the only radioactive lipid detectable 
was the ganglioside GM1. 
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Figure 24: Metabolic fate of the exogenous administered GM1 in F508del-CFBE cells, in presence or not of 
5 μM VX-809 and VX-770 
F508del-CFBE were treated with 50 μM GM1 and 90 nM of 3H-GM1 (corresponding to 0,09 µCi) and with 5 
μM VX-809 and VX-770 (VX); CTRL cells were not treated with potentiator and corrector. After 12, 24 and 48 
hours the cells were lysed and resuspended in ice-cold water and briefly subjected to sonication before being 
lyophilized. The samples were then subjected to lipid extraction with CHCl3:CH3OH:H2O 20:10:1 (v:v:v). Each 
sample was loaded on HPTLC using the same amount of radioactivity. Lipids were separated, using the 
solvent system CHCl3:CH3OH:CaCl2 50:42:11 by vol and then revealed by digital autoradiography. 
 
With this experiment, I have demonstrated that the exogenously administered GM1 is not 
metabolized by the cells at least up to 48 hours. 
After that, I verified if corrected F508del-CFTR localizes in the same PM microenvironment of 
GM1, as previously demonstrated for the WT-CFTR, also in this case by photolabelling 
experiments.  
F508del-CFBE cells were seeded and treated for 48 hours as follows:  
 Untreated cells as control 
 5 μM VX-809 and 5 μM VX-770 
 50 μM GM1 
 5 μM VX-809 and 5 μM VX-770 + 50 μM GM1 
For the last 6 hours 3H-GM1-N3 was administered to the cells in dark conditions. After the 
incubations, the cells were washed and illuminated for 40 minutes with UV rays and processed as 
previously described. Consequently, I performed a SDS-PAGE and relative immunoblotting analysis 
to separate and identifiy the two bands of CFTR. After Western blotting, the same PVDF was 
subjected to autoradiography to reveal the presence of potential radioactive bands. The results 
obtained are shown in figure 25. In control cells, Western blot analyses revealed the presence of 
only the b-band of CFTR without the presence in the digital autoradiography of any radioactive 
band corresponding to the mature form of CFTR. The same result was observed for the conditions 
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of double treatment with the corrector and potentiator. Interestingly, in the case of treatment 
with exogenous GM1 by Western blot, I observed a remarkable staining of the mature form of 
CFTR and in the digital autoradiography I detected a radioactive band corresponding to the c-band 
of CFTR. These data suggest that the rescued mutated protein interacts directly with ganglioside 
GM1 and were located in the same PM microenvironment.  
 
 
 
Figure 25: Study of CFTR-GM1 association in F508del-CFBE cells treated with corrector VX-809 and 
potentiator VX-770 
F508del-CFBE were treated with corrector VX-809 and potentiator VX-770, in presence or not of 50 μM GM1 
for 48 hours, then the cells were treated with tracer quantity of 3H-GM1-N3 in dark conditions and after 6 
hours, were illuminated under UV light, harvested and subjected to SDS-PAGE and Western Blotting 
analyses. After this, the same PVDF was subjected to autoradiography to revealed the radioactivity 
Left: Immunoblotting analysis for CFTR identification, Right: digital autoradiography of the same PVDF 
 
I verified the impact of GM1 administration on the lipid composition of treated cells. I treated or 
not F508del-CFBE cells with 50 μM GM1 for 48 hours and after that the cells were collected, lysed 
and lyophilised; lipids from the lyophilised samples were extracted with 
chloroform:methanol:water 20:10:1 (v:v:v) and subjected to a two-phase Folch’s partitioning to 
obtain the aqueous (AP) and the organic phases (OP). Aliquots of the organic phase were then 
subjected to alkaline treatment to remove glycerophospholipids (MetOP) as previously described. 
The lipids were then separated by HPTLC using different solvent systems and the results are shown 
in figure 26. As it is possible to see, I didn’t detect any significant difference in neutral lipid 
composition upon GM1 treatment, for the exclusion of cholesterol that slightly increase.  
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Figure 26: Evaluation of ganglioside GM1 administration on the F508del-CFBE cell lipids composition 
F508del-CFBE cells were treated for 48 hours with 50 μM GM1 and then subjected to lipid analysis. Cells 
lysates were subjected to lipid extraction with CHCl3:CH3OH:H2O 20:10:1 (v:v:v). Total lipid extracts were 
further subjected to a two-phase partitioning resulting in the separation of an aqueous phase (AP) 
containing gangliosides and in an organic phase (OP) containing all other lipids. Aliquots of the organic 
phases were then subjected to alkaline treatment to remove glycerophospholipids (MetOP).  
(A): neutral lipids were evaluated loading TLC with a volume of MetOP equivalent to 500 µg of cell lysate. 
Lipids were separated using the solvent system CHCl3:CH3OH:H2O 110:40:6 (v:v:v) and visualized by 
anisaldehyde reagent. 
(B): phospholipids were evaluated loading TLC with a volume of OP equivalent to 200 µg of cell lysate. Lipids 
were separated using the solvent system CHCl3:CH3OH:Acetic Acid: H2O 30:20:2:1 (v:v:v), and visualized with 
phosphorus reactive.  
(C):cholesterol was evaluated loading TLC with a volume of MetOP equivalent to 300 µg of cell lysate. Lipids 
were separated using the solvent system Exane: Etil Acetate 3:2 (v:v) and visualized by anisaldehyde 
reagent.  
GlcCer: glucosylceramide; LacCer: Lactosylceramide; SM: sphingomyelin; Gb3: Globoatriosylceramide; PC: 
phosphatidylcholine, PE: phosphatidylethanolammine, chol: Cholesterol 
 
As emerges from the literature the ganglioside GM1, hasn’t only a structural role in membrane 
architecture, but it is also a bioactive signalling molecules with potential toxic effect. 
I performed MTT assay to verify the possible cytotoxicity of the exogenously administered GM1. 
F508del-CFBE cells were seeded at the same density into 96-microplate and treated with 50 μM of 
exogenous GM1 and MTT assay was performed after 6, 12, 24 and 48 hours. As sown in figure 27 I 
observed only an apparent, but not statistically significant reduction in cell viability upon the 
treatment.  
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Figure 27: Cell viability of F508del-CFBE treated with 50 μM of ganglioside GM1 
Cells were seeded at the density of 13500 cells/cm2 into 96 multi-well, and at the end of every time-point, 
cell viability was evaluated by MTT assay. The data were expressed as % VS untreated cells. 
 
Subsequently, I further investigated the possible cytotoxic effects of GM1 evaluating, by Western 
blot analyses, the markers of cellular damage such as caspase-3 and Cyclin D2.  
F508del-CFBE cells were treated in the same conditions of the previous experiment, and after 6, 
12, 24 and 48 hours the cells were collected, lysed and subjected to SDS-PAGE and 
immunoblotting analysis. The results of both Western blot are shown in figure 28, where it is 
possible to exclude in treated cells the activation of the apoptosis since I could not detect the 
presence of the cleaved form of caspase 3. In addition, also the level of Cyclin D2 is the same in 
control and treated cells, indicating that GM1 does not alter cell proliferation.  
 
 
 
 
 
Figure 28: Evaluation by immunoblotting analyses of the effect of GM1 treatment on the cell damage 
biomarkers 
Representative Western-blot images of pro-caspase 3, its cleaved form and of cyclin D2 protein expression 
in F508del-CFBE cells treated with 50 µM of GM1 for 6, 12, 24 and 48 hours. β-actin was evaluated as 
loading control.  
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The exogenous administration of GM1 antagonises the negative effect of 
potentiator VX-770 on F508del-CFTR plasma membrane stability 
 
To deeply investigate the relationship between Orkambi® and GM1 in the PM stabilization of 
F508del-CFTR, I performed experiments on F508del-CFBE cells corrected for GM1 content and 
subjected to the single treatment with corrector and potentiator. 
The experimental plan consisted in the treatment of F508 del-CFBE cells as follows: 
 untreated cells  
 5 μM VX-809 
  5 μM VX-770 
  5 μM VX-809 + 5 μM VX-770 
The above 4 conditions in presence or not of 50 μM GM1. 
The cells were treated for 48 hours after which they were collected and finally lysed to perform an 
immunoblotting analysis to reveal the role of GM1 on F508del-CFTR maturation upon the different 
pharmacological treatments. As reported in the representative immunoblotting images in figure 
29, the treatment with only GM1 does not increase the maturation of F508del-CFTR as occurs in 
the presence of corrector VX-809. These results confirm only those presented before regarding 
the positive effect of GM1 in case of the double treatment with corrector and potentiator. 
Moreover in presence of Orkambi® and GM1, the rescued mature F508del-CFTR, that was lost in 
the treatment without GM1, has been recovered. 
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Figure 29: Exogenous administration of GM1 increased the plasma membrane stability of F508del-CFTR 
rescued by Orkambi® 
Representative Western-blot analysis of the content of CFTR performed in F508del-CFBE cells subjected to 
the treatments with corrector VX-809, potentiator VX-770 individually or in combination and subjected or 
not to exogenous treatment with 50 µM GM1. GAPDH was evaluated as loading control.  
C band: mature and glycosylated form of protein CFTR, inserted in plasma membrane  
B band: immature form of protein CFTR  
 
Subsequently, I analysed in the same samples, the cellular levels of the CFTR scaffolding protein 
NHERF-1, ezrin and its bioactive form p-ezrin. As sown in figure 30, once again, I observed an 
increase of NHERF-1, ezrin and p-ezrin after the treatment with VX-809, while in presence of 
potentiator VX-770 I observed their decrease as previously demonstrated. Surprisingly, when the 
cells were treated with also GM1, I observed an increase of protein level in all the conditions. This 
result suggests that GM1 plays an active role in the control of CFTR PM interactome. 
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Figure 30: The treatment with GM1 abolishes the negative effect of VX-770 on CFTR scaffolding proteins 
Immunoblotting analyses of CFTR-scaffolding protein NHERF-1, ezrin and its bioactive form p-ezrin were 
performed on F508del-CFBE cells subjected to the treatment with corrector VX-809, potentiator VX-770 
individually or in combination and subjected or not to treatment with 50 μM GM1. GAPDH was evaluated as 
loading control. 
Left: F508del-CFBE without GM1 
Right:F508del-CFBE treated with GM1 
 
I verified the effect of the different drugs treatments in terms of both GM1 association and lipid 
composition. I first performed an immunostaining with cholera toxin after treating the cells as 
previously described in latest experiment, and as shown in figure 31 the pharmacological 
treatments did not alter the GM1 cellular uptake, and compensate the induced lack of GM1 in 
treated cells. 
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Figure 31: GM1 administration compensate the negative effect of the pharmacological treatment on 
GM1 levels in F508del-CFBE cells 
F508del-CFBE cells were treated with 5 μM corrector VX-809, potentiator VX-770 individually or in 
combination and subjected or not to exogenous treatment with 50 µM GM1. In the image is shown the TLC 
immunostaining with cholera toxin: briefly, TLC was loaded with aqueous volume equivalent to the same 
amount of total cell protein (150 µg each). After chromatographic separation with solvent system: 
CHCl3:CH3OH:CaCl2 50:42:11 by vol., TLC plates were fixed with a polyisobuthylmethacrylate solution, air 
dried and incubated with 3% BSA in PBS for 1 hour. Plates were then incubated with cholera toxin at 10 
μg/mL in 1% BSA in PBS for 1 hours at room temperature (RT). After washes with PBS the immunoreactive 
bands were revealed using o-phenylenediamine (OPD)/H2O2 in 0.05 M citrate-phosphate buffer pH 5.0. 
 
In all the conditions tested I didn’t observe any significant change between pharmacological 
treated cells in presence or not of GM1 in term of: glucosylceramide, lactosylceramide, 
globoatriosylceramide, sphingomyelin and glycerophospholipids composition (figure 32). 
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Figure 32: Evaluation of lipid composition in F508del-CFBE cells treated with corrector VX-809, 
potentiator VX-770 and subjected or not to 50 µM GM1 
F508del-CFBE cells were treated with 5 μM corrector VX-809, potentiator VX-770 individually or in 
combination and subjected or not to exogenous treatment with 50 µM GM1 and then subjected to lipid 
analysis. Cells lysates were subjected to lipid extraction with CHCl3:CH3OH:H2O 20:10:1 (v:v:v). Total lipid 
extract were further subjected to a two-phase partitioning resulting in the separation of an aqueous phase 
(AP) containing gangliosides and in an organic phase (OP) containing all other lipids. Aliquots of the organic 
phases were then subjected to alkaline treatment to remove glycerophospholipids (MetOP).  
(A): neutral lipids were evaluated loading TLC with a volume of MetOP equivalent to 500 µg of cell lysate. 
Lipids were separated using the solvent system CHCl3:CH3OH:H2O 110:40:6 (v:v:v) and visualized by 
anisaldehyde. 
(B): phospholipids were evaluated loading TLC with a volume of OP equivalent to 200 µg of cell lysate. Lipids 
were separated using the solvent system CHCl3:CH3OH:Acetic Acid: H2O 30:20:2:1 (v:v:v), and visualized with 
phosphorus reactive.  
GlcCer: glucosylceramide; LacCer: Lactosylceramide; SM: sphingomyelin; Gb3: Globoatriosylceramide; PC: 
phosphatidylcholine, PE: phosphatidylethanolammine 
 
Finally, I analyzed cholesterol content and surprisingly I noticed that its content didn’t vary after 
GM1 administration in fact is still decreased when the cells were treated with potentiator VX-770, 
as it is shown in figure 33. 
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Figure 33: VX-770 reduces the cholesterol levels in F508del-CFBE cells, under treatment with corrector VX-
809, potentiator VX-770 and subjected or not to 50 μM GM1 
F508del-CFBE cells were treated with corrector VX-809, potentiator VX-770 individually or in combination 
and subjected or not to exogenous treatment with 50 µM GM1 and then subjected to lipid analysis. Cells 
lysates were subjected to lipid extraction with CHCl3:CH3OH:H2O 20:10:1 (v:v:v). Total lipid extract were 
further subjected to a two-phase partitioning resulting in the separation of an aqueous phase (AP) 
containing gangliosides and in an organic phase (OP) containing all other lipids. Aliquots of the organic 
phases were then subjected to alkaline treatment to remove glycerophospholipids (MetOP). 
Cholesterol was evaluated loading TLC with a volume of MetOP equivalent to 300 µg of cell lysate. Lipids 
were separated using the solvent system Exane: Etil Acetate 3:2 (v:v) and visualized by anisaldehyde.  
Chol: cholesterol 
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Treatment with GM1 improves CFTR function 
 
Until now, I demonstrated that the recovery of the cell content of GM1 causes important effects 
on the stability of F508del-CFTR rescued by the Orkambi® treatment. I demonstrated for the first 
time that in WT-CFBE cells, GM1 is closely associated to CFTR, and this association is maintained 
also by the rescued F508del-CFBE upon the treatment of the cells with exogenous GM1. In 
addition, I demonstrated also that ganglioside GM1 is an adjuvant for Orkambi® therapy on 
stabilizing F508del-CFTR at PM by the recruitment of the CFTR scaffolding proteins NHERF-1, ezrin 
and p-ezrin.  
However, I didn’t have information regarding the effect of GM1 on the recovery of F508del-CFTR 
channel activity. To this purpose, I performed, in collaboration with Dr. Anna Tamanini from the 
university Hospital of Verona, assays aimed to verify the activity of corrected-CFTR. To perform 
these assays I took advantage by the use of F508del-CFBE-YFP cells. These cells were stably 
transfected with the halide-sensitive yellow fluorescent protein (HS-YFP) YFPH148Q/I152L, 
allowing to rapidly test the effect of modulators by measuring Iodide influx [165], [166], [167]. In 
addition, since cells were maintained alive at 37°C, CFTR activity can be assessed in physiological 
conditions. In particular, the differences in CFTR activity were measured by detecting channel 
activity after the use of a stimulation cocktail and comparing it with the activity measured after 
treatment with CFTR inhibitor cocktail. In this way was possible to determine if the treatment with 
CFTR-modulators and GM1 might affect CFTR activity. 
The cells were treated for 48 hours as follows: 
 5 μM VX-809 
 50 μM GM1 
 5 μM VX-809 + 50 μM GM1 
At the end of the incubation, the activity of CFTR was measured. As it possible to notice from the 
graph (Figure 34), I detected an increase on F508del-CFTR activity, also after treatment with just 
GM1 with respect to control cells; the activity of the channel after treatment with corrector VX-
809 had increased too, as expected. Surprisingly when F508del-CFBE cells have been treated with 
both GM1 and VX-809 the activity was the highest. These data suggest that GM1 may have a 
corrective effect on CFTR. 
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Figure 34: The exogenous administration of ganglioside GM1 potentiates the effect of corrector VX-809 
CFBE-YFP F508del-CFTR cells were seeded on round glass coverslips and were preincubated for 48 hours 
with vehicle (DMSO), 5 μM VX-809 and 50 μM GM1 individually or in combination. At the end of 48 hours 
cells were incubated with stimulation cocktail (20 μM forskolin and 5μM VX-770, in presence or not of 10 
μM of CFTR inhibitor (CFTRInh-172) for 30 minutes. CFTR dependent chloride efflux was assayed by single-
cell fluorescence imaging analysis of YFP fluorescence quenching by iodide. Fluorescence coming from each 
single cell was recorded.  
Each bar corresponds to the mean ±SEM of at least three different experiments. Statistical comparison were 
made using an unpaired Mann-Whitney (*p<0,05, **p<0,01 and ***p<0,001). 
 
Then I verified if GM1 might have the same activity also in combination with potentiator VX-770. 
For this reason, the cells were treated for 48 hours as follows: 
 5 μM VX-770 
 50 μM GM1 
 5 μM VX-770 + 50 μM GM1 
As emerge from the graph reported in figure 35, after treatment with VX-770 I could observe a 
little increase with respect to control cells, less marked than the increment detected with GM1 
alone. Interestingly, when F508del-CFBE cells have been treated with GM1 and VX-770, the 
activity of CFTR has decreased with respect to the activity measured in the cells treated with just 
GM1, suggesting that as previously observed, the treatment with VX-770 had a negative effect, 
probably due to a destabilization of CFTR at PM. 
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Figure 35: Ganglioside GM1 has itself a corrective effect and antagonize the negative effect of VX-770 
CFBE-YFP F508del-CFTR cells were seeded on round glass coverslips and were preincubated for 48 hours 
with vehicle (DMSO), 5 μM VX-770 and 50 μM GM1 individually or in combination. At the end of 48 hours 
cells were incubated with stimulation cocktail (20 μM forskolin and 5μM VX-770, in presence or not of 10 
μM of CFTR inhibitor (CFTRInh-172) for 30 minutes. CFTR dependent chloride efflux was assayed by single-
cell fluorescence imaging analysis of YFP fluorescence quenching by iodide. Fluorescence coming from each 
single cell was recorded.  
Each bar corresponds to the mean ±SEM of at least three different experiments. Statistical comparison were 
made using an unpaired Mann-Whitney (*p<0,05, **p<0,01 and ***p<0,001). 
 
Finally, to complete the study, I analysed the effect of GM1 treatment in combination with 
Orkambi® therapy. F508del-CFBE cells were subjected for 48 hours to the following treatments: 
 5 μM VX-809 
 5 μM VX-809 +5 μM VX-770  
 5 μM VX-809 +5 μM VX-770 + 50 μM GM1 
Then CFTR activity was revealed; the results are shown in the following figure 36. 
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Figure 36: GM1 is an adjuvant for Orkambi® therapy  
CFBE-YFP F508del-CFTR cells were seeded on round glass coverslips and were preincubated for 48 hours 
with vehicle (DMSO), with 5 μM VX-809, with 5 μM VX-809 +5 μM VX-770, and with 5 μM VX-809 +5 μM VX-
770 + 50 μM GM1. At the end of 48 hours cells were incubated with stimulation cocktail (20 μM forskolin 
and 5μM VX-770, in presence or not of 10 μM of CFTR inhibitor (CFTRInh-172) for 30 minutes. CFTR 
dependent chloride efflux was assayed by single-cell fluorescence imaging analysis of YFP fluorescence 
quenching by iodide. Fluorescence coming from each single cell was recorded.  
Each bar corresponds to the mean ±SEM of at least three different experiments. Statistical comparison were 
made using an unpaired Mann-Whitney (*p<0,05, **p<0,01 and ***p<0,001). 
 
As previously observed, also in this case the treatment with VX-809 causes an increase in CFTR 
activity, while the treatment with the combination of potentiator and corrector, decreased this 
recovered function. Surprisingly, when the F508del-CFBE cells were subjected to Orkambi® 
therapy with 50 μM GM1, the activity was the highest observed, with respect to the other 
analysed conditions.  
To conclude I can summarize that GM1 has also an important effect on CFTR activity, suggesting its 
use as adjuvant for Orkambi® therapy. 
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Several studies reported in literature, support the active role of sphingolipids in CF. Indeed, 
sphingolipids alterations in CF bronchial epithelial cells seem to be involved in the establishment 
of the high pro-inflammatory state typical of CF patients as well as in the inflammatory response 
and susceptibility to bacterial infections.  
A peculiar role during the bacterial infections, seems to be played by ceramide. Increased levels of 
PM ceramide in CF bronchi correlates with the pro-inflammatory status typical of CF lung disease 
[134, 168]. Furthermore, the GSLs asialo-GM1 and asialo-GM2 could operate as receptor for P. 
aeruginosa binding, even if a direct proof with the clinical relevant strains of this bacterium has 
not been available so far [169, 170]. 
Recent data have described for the first time a direct relationship between CFTR and sphingolipids 
in human bronchial epithelial cells. In 2014 Itokazu and colleagues demonstrated that CFTR-
silenced cells are characterized by a 60% decrease in the glycosphingolipid GM1 content, which is 
responsible for a reduced β1-integrin activation with a consequent decreased phosphorylation of 
FAK and CAS and block of cell motility. To note, the addition of GM1 to CFTR-silenced cells was 
able to revert the phenotype [35]. Ramu and colleagues described that the ceramide produced at 
the cell surface through the sphingomyelin (SM) hydrolysis promoted by bacterial infection 
induces the clusterization of CFTR making difficult the channel activation by the phosphorylation 
of regulatory domain [149]. Moreover, several studies reported that CFTR at the apical membrane 
of epithelial cells is associated with lipid rafts [34].  
As it is well known, lipids rafts are specific portion of the PM enriched on saturated lipids, 
sphingolipids, and cholesterol that by the recruitment and stabilization of a selected number of 
proteins, organize macromolecular complexes involved in the control of cell signaling.  
An impressive study performed by Pankow S. and colleagues, reveals that PM CFTR interactome is 
composed of a wide number of proteins involved in the control of the channel activity and in its 
stabilization at the PM level [169, 170]. Interestingly, they showed that in case of F508del-CFTR 
the macromolecular complex is completely different with respect to the one of WT-CFTR.  
No information has been available so far on the lipid-based interactome involved in the control of 
CFTR properties. However, the existence of a direct correlation between the expression at the PM 
of CFTR and the cellular levels of GM1 gets to speculate on the ganglioside as possible actor. 
To investigate this aspect, I took advantage of an experimental procedure developed in the 
laboratory where I performed my PhD project. In particular, by the use of a radioactive and 
photoactivable GM1 derivative, I demonstrated for the first time that in bronchial epithelial cells, 
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CFTR and GM1 reside in the same PM microenvironment, and this correlation is missed in case of 
F508del-CFTR. 
Since the ganglioside GM1 is an important bioactive lipid involved in the control and stabilization 
of several proteins, this result opens a new scenario in the study of the CFTR and includes the 
ganglioside in the cluster of molecules belonging to CFTR interactome that changes in presence of 
the mutation F508del.  
It is now clear that in a such complicated scenario which comprises several actors beside to CFTR, 
the therapies based on the rescue of mutated channel need to take in account that together with 
the recovery of CFTR, it is important to restore also its interactome both in terms of proteins and 
lipids composition.  
A clear example is represented by the failure in the chronic use of Orkambi® for restoring the 
function of F508del-CFTR in CF cells. Orkambi® is a combination of corrector VX-809 and 
potentiator VX-770 (lumacaftor-Ivacaftor), approved for patients homozygous for the F508del 
mutation. Despite initial beneficial effects, the chronic treatment doesn’t results efficacious. A 
recent study also shows that there is a potential non-specific effect of VX-770 on the lipid bilayer 
and suggests that this effect may account for its destabilizing effect on VX-809-rescued F508del-
CFTR, underlining an important role of lipids of the PM in stabilizing CFTR [171]. Interestingly, we 
observed in F508del-CFTR bronchial epithelial cells that Orkambi® treatment induces a decrease in 
GM1 content further supporting a possible role of the ganglioside in the control of CFTR turnover.  
To investigate this aspect, I evaluated the effect of the exogenous administration of GM1 on CFTR 
maturation in bronchial epithelial cells overexpressing the F508del-CFTR. Firstly I found that the 
cell take up the ganglioside without significant variation in the content of the other cell lipids but 
without an improvement in the maturation of F508del-CFTR. This result was quite expected 
because the mutation F508del impairs the folding of the protein in the ER where GM1 is not 
present, even when it is exogenously administered to the cells. For this reason I repeated the 
experiments in cells treated or not with GM1 and with the corrector VX-809. Interestingly, I found 
that the combined treatment results in an increase of the cellular levels of the mature form of 
F508del-CFTR and of its scaffolding proteins NHERF-1 and p-ezrin. In addition, by the use of 
F508del-CFBE-YFP cells, I evaluated the effect of GM1 together with VX-809 on CFTR activity. The 
results obtained revealed that the treatment with GM1 induces a slight but significant increase of 
the channel activity of the rescued protein, suggesting that the exogenous administration of GM1 
restores the PM properties allowing the establishment of the proper physiological work condition 
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for the VX-809-rescued F508del-CFTR. To further improve the activity of VX-809-rescued F508del-
CFTR, the cells were treated also with the potentiator VX-770. In the absence of GM1, we found 
that the treatment with VX-770 abolishes the maturation of F508del-CFTR promoted by VX-809 
with the consequent decrease in the cellular levels of the scaffolding proteins NHERF-1 and p-
ezrin. Whereas, the concomitant treatment of the cells with VX-809, VX-770 and GM1 antagonizes 
the negative effect of the potentiator in terms of F508del-CFTR maturation and cellular levels of 
the CFTR scaffolding proteins. Also in this case, by the use of F508del-CFBE-YFP I found that the 
treatment with corrector, potentiator and GM1 induces an important recovery of the channel 
activity.  
All together, the results obtained point out that the exogenous administered GM1 becomes 
component of the PM of bronchial epithelial cells where it is able to re-organize a specific cell 
surface microenvironment that by the recruitment of scaffolding proteins stabilizing the F508del-
CFTR matured by VX-809 and potentiated with VX-770 (Figure 37).  
 
 
Figure 37: The exogenous administration of GM1 organizes plasma membrane CFTR microenvironment  
 
In addition, since GM1 does not show any toxic effect on the CF bronchial epithelial cells it is 
reasonable to speculate on its use as adjuvant for the Orkambi® therapy.  
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